var title_f32_56_33664="Levocabastine: Drug information";
var content_f32_56_33664=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Levocabastine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12929905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12931135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/49/6932?source=see_link\">",
"       Levocabastine (nasal): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22179?source=see_link\">",
"       Levocabastine (ophthalmic): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16761 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-EA0AF42627-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_56_33664=[""].join("\n");
var outline_f32_56_33664=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/49/6932?source=related_link\">",
"      Levocabastine (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22179?source=related_link\">",
"      Levocabastine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_56_33665="Open cystectomy cde";
var content_f32_56_33665=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Open ovarian cystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 501px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (C) Sharp excision to separate the base of the cyst from the ovary. (D) The deep tissues of the ovary are reapproximated using fine absorbable sutures avoiding the surface of the ovary. (E) The ovarian cortex is approximated with no visible sutures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_56_33665=[""].join("\n");
var outline_f32_56_33665=null;
var title_f32_56_33666="Serpiginous-like choroiditis";
var content_f32_56_33666=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Serpiginous-like choroiditis due to ocular TB",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Highly pigmented serpiginous-like choroiditis in a patient with pulmonary TB.",
"    <div class=\"footnotes\">",
"     TB: tuberculosis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_56_33666=[""].join("\n");
var outline_f32_56_33666=null;
var title_f32_56_33667="Tubes for closed suction drainage";
var content_f32_56_33667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F59098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F59098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Tubes for closed suction drainage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 416px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Many sizes are available.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_56_33667=[""].join("\n");
var outline_f32_56_33667=null;
var title_f32_56_33668="Wrap technique";
var content_f32_56_33668=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ribbon gauze method of ring removal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 271px; height: 587px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The success of this technique depends upon tight, close wrapping of the digit or penis. Do not attempt this technique if the patient has ischemia of the digit or penis or an open wound, fracture, or dislocation distal to the ring. A) After appropriate analgesia, place one end of a 2.0 or 3.0 suture, Penrose drain, or umbilical tape 20 to 25 inches (0.5 to 0.6 m) in length under the ring from the proximal to the distal side with 5 inches (12.5 cm) of material remaining proximally. B) Wrap the suture material, drain, or tape tightly around the digit or penis beginning at the distal aspect of the ring. Overlap the wrappings so that no tissue is visible. Continue wrapping beyond the proximal interphalangeal joint of the digit or beyond the coronal sulcus of the penis. C) Once the wrapping is complete, pull on the proximal end of the wrapping material so that the ring is removed from the finger or penis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fuchs SM. Ring removal. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_56_33668=[""].join("\n");
var outline_f32_56_33668=null;
var title_f32_56_33669="Clinical manifestations of hypercalcemia";
var content_f32_56_33669=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of hypercalcemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/56/33669/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/56/33669/contributors\">",
"     Elizabeth Shane, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/56/33669/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/56/33669/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/56/33669/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/56/33669/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/56/33669/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia can be produced by a variety of disorders, but primary hyperparathyroidism and malignancy account for most cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/22/28007?source=see_link\">",
"     \"Etiology of hypercalcemia\"",
"    </a>",
"    .) It may be associated with a spectrum of clinical manifestations (",
"    <a class=\"graphic graphic_table graphicRef54647 \" href=\"mobipreview.htm?41/50/42795\">",
"     table 1",
"    </a>",
"    ), ranging from few if any symptoms if the hypercalcemia is mild",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic to obtundation and coma if it is severe",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33669/abstract/1\">",
"     1",
"    </a>",
"    ]. The symptoms and signs associated with hypercalcemia are typically independent of the etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33669/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with mild hypercalcemia (calcium &lt;12",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    may be asymptomatic, or they may report nonspecific symptoms, such as constipation, fatigue, and depression. A serum calcium of 12 to 14",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3 to 3.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    may be well-tolerated chronically, while an acute rise to these concentrations may cause marked symptoms, including polyuria, polydipsia, dehydration, anorexia, nausea, muscle weakness, and changes in sensorium. In patients with severe hypercalcemia (calcium &gt;14",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3.5",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    there is often progression of these symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33669/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review those symptoms directly associated with hypercalcemia. The clinical manifestations more directly associated with hyperparathyroidism and the diagnostic approach to and treatment of hypercalcemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1338?source=see_link\">",
"     \"Clinical manifestations of primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20934?source=see_link\">",
"     \"Diagnostic approach to hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEUROPSYCHIATRIC DISTURBANCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of mild neuropsychiatric disturbances have been associated with hypercalcemia, mostly in patients with primary hyperparathyroidism. The most common symptoms have been anxiety, depression, and cognitive dysfunction. Improvement in some or all of these symptoms has been described after correction of the hyperparathyroidism, but these reports are of uncontrolled cases and therefore difficult to evaluate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1338?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations of primary hyperparathyroidism\", section on 'Neuropsychiatric disturbances'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of primary hyperparathyroidism\", section on 'Neuropsychiatric'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More severe symptoms, including lethargy, confusion, stupor, and coma may occur in patients with severe hypercalcemia (calcium &gt;14",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3.5",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    from any cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33669/abstract/1\">",
"     1",
"    </a>",
"    ]. These symptoms are more likely to occur in the elderly and in those with rapidly rising calcium concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33669/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GASTROINTESTINAL ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal symptoms, such as constipation, anorexia, and nausea occur commonly. Constipation may be related to decreased smooth muscle tone",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abnormal autonomic function. Pancreatitis and peptic ulcer disease occur less frequently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33669/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. Proposed mechanisms for the development of pancreatitis include deposition of calcium in the pancreatic duct and calcium activation of trypsinogen within the pancreatic parenchyma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33669/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. In rats, acute hypercalcemia causes a dose-dependent increase in serum amylase and morphologic characteristics of acute pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33669/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peptic ulcer disease has been described in patients with hypercalcemia due to primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33669/abstract/4\">",
"     4",
"    </a>",
"    ] and may be caused by calcium-induced increases in gastrin secretion. In patients with MEN1 with coexisting Zollinger-Ellison syndrome and hyperparathyroidism, parathyroidectomy alone has led to a significant reduction in serum gastrin concentrations and acid secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33669/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RENAL DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important renal manifestations are polyuria, resulting from decreased concentrating ability in the distal tubule, nephrolithiasis, and acute and chronic renal insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nephrogenic diabetes insipidus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic hypercalcemia leads to a defect in concentrating ability that may induce polyuria and polydipsia in up to 20 percent of patients. The mechanism is incompletely understood, but the downregulation of aquaporin-2 water channels, and calcium deposition in the medulla with secondary tubulointerstitial injury and impaired generation of the interstitial osmotic gradient may play important roles. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21545?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and causes of nephrogenic diabetes insipidus\", section on 'Hypercalcemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, some studies have demonstrated that activation of the normal calcium-sensing receptor by increases in the plasma calcium concentration can directly impair concentrating ability by affecting both the loop of Henle and the collecting tubules. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19258?source=see_link\">",
"     \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21545?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and causes of nephrogenic diabetes insipidus\", section on 'Hypercalcemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The combination of polyuria and diminished fluid intake secondary to gastrointestinal symptoms (nausea) can lead to dehydration, which exacerbates hypercalcemia and related symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nephrolithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;When hypercalcemia is due to primary hyperparathyroidism or sarcoidosis, it is often longstanding, and the resulting chronic hypercalciuria may cause nephrolithiasis. Increased calcitriol production may also play an important role in both diseases. The occurrence of nephrolithiasis in patients with these disorders is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1338?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations of primary hyperparathyroidism\", section on 'Nephrolithiasis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40438?source=see_link&amp;anchor=H4#H4\">",
"     \"Renal disease in sarcoidosis\", section on 'Nephrolithiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Renal tubular acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic hypercalcemia infrequently causes type 1 (distal) renal tubular acidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33669/abstract/12\">",
"     12",
"    </a>",
"    ]. The ensuing hypercalciuria and hypocitraturia can contribute to the development of nephrolithiasis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/26/23973?source=see_link\">",
"     \"Nephrolithiasis in renal tubular acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of renal insufficiency in individuals with hypercalcemia is related to the degree and duration of hypercalcemia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild hypercalcemia is rarely associated with renal insufficiency. In randomized trials of two to three years duration, there is little evidence that renal function deteriorates in patients with mild chronic hypercalcemia due to hyperparathyroidism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=see_link&amp;anchor=H9#H9\">",
"       \"Management of primary hyperparathyroidism\", section on 'Biochemical abnormalities'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Higher elevations in the serum calcium concentration (serum calcium values of 12 to 15",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [3 to 3.75",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      can lead to a reversible fall in glomerular filtration rate that is mediated by direct renal vasoconstriction and natriuresis-induced volume contraction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/56/33669/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Long-standing hypercalcemia and hypercalciuria may lead to calcification, degeneration, and necrosis of the tubular cells, and eventual tubular atrophy and interstitial fibrosis and calcification (nephrocalcinosis). Nephrocalcinosis, a condition observed in over one-half of hypercalcemic patients with renal insufficiency, is the most common cause of chronic kidney disease in sarcoidosis. In comparison, nephrocalcinosis appears to be uncommon in patients with primary hyperparathyroidism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/56/33669/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40438?source=see_link&amp;anchor=H3#H3\">",
"       \"Renal disease in sarcoidosis\", section on 'Hypercalciuria and hypercalcemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/43/17081?source=see_link\">",
"       \"Nephrocalcinosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute hypercalcemia directly shortens the myocardial action potential, which is reflected in a shortened QT interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33669/abstract/16\">",
"     16",
"    </a>",
"    ]. Although there does not appear to be any clinically important effect of moderate hypercalcemia on cardiac conduction or the prevalence of supraventricular or ventricular arrhythmias in patients with primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33669/abstract/17\">",
"     17",
"    </a>",
"    ], arrhythmia has been described in patients with severe hypercalcemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33669/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In addition, ST-segment elevation mimicking myocardial infarction has been reported in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33669/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-standing hypercalcemia, as occurs in primary or secondary hyperparathyroidism, can lead to other cardiac abnormalities, including deposition of calcium in heart valves, coronary arteries, and myocardial fibers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33669/abstract/23\">",
"     23",
"    </a>",
"    ]; hypertension; and cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1338?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations of primary hyperparathyroidism\", section on 'Cardiovascular'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MUSCULOSKELETAL SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Profound muscle weakness was prominent in the original description of patients with hyperparathyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33669/abstract/24\">",
"     24",
"    </a>",
"    ]. This is not the case in the majority of such patients today but mild weakness (due in part to earlier diagnosis) may be apparent if looked for [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33669/abstract/25\">",
"     25",
"    </a>",
"    ]. In one prospective study, for example, nine patients were tested for neuromuscular performance before and four weeks after parathyroid surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33669/abstract/25\">",
"     25",
"    </a>",
"    ]. All had an increase in muscle strength and improvement in fine motor movement, while there was no change in nonoperated patients. Weakness can be an important feature of other causes of hypercalcemia such as malignancy, but this can be a manifestation of the underlying illness rather than from hypercalcemia alone.",
"   </p>",
"   <p>",
"    Bone pain can occur in individuals with hypercalcemia due to malignancy or primary hyperparathyroidism. A reduction in cortical bone mass may occur in individuals with hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1338?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations of primary hyperparathyroidism\", section on 'Bone mineral density'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PHYSICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are usually no specific physical findings of hypercalcemia other than those that might be related to an underlying disease such as malignancy and nonspecific findings related to dehydration. Band keratopathy, a reflection of subepithelial calcium phosphate deposits in the cornea, is a very rare finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33669/abstract/26\">",
"     26",
"    </a>",
"    ]. It extends as a horizontal band across the cornea in the area that is exposed between the eyelids; calcium salts probably precipitate in that site because of the higher local pH induced by the evaporation of CO2. It is usually detected by slit-lamp examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia can affect a variety of organ systems (",
"    <a class=\"graphic graphic_table graphicRef54647 \" href=\"mobipreview.htm?41/50/42795\">",
"     table 1",
"    </a>",
"    ). The symptoms of hypercalcemia depend upon both the degree of hypercalcemia and the rate of onset of the elevation in the serum calcium concentration. In addition, there is individual variation in the manifestation of symptoms.",
"   </p>",
"   <p>",
"    Patients with mildly elevated serum calcium concentrations (&lt;12",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3.0",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    are often asymptomatic, particularly if the elevation in serum calcium is chronic. Patients with moderately elevated calcium (12 to 14",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    may have symptoms of polyuria, polydipsia, anorexia, nausea, and constipation. As the calcium concentration increases, symptoms can become more severe and include weakness, difficulty concentrating, confusion, stupor, and coma. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Neuropsychiatric disturbances'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The most common renal manifestation of hypercalcemia is polyuria, due to a defect in concentrating ability, leading to dehydration. Chronic hypercalcemia associated with hypercalciuria can lead to nephrolithiasis or nephrocalcinosis. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Renal dysfunction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although uncommon, severe hypercalcemia can be associated with cardiac arrhythmia. Chronic hypercalcemia may lead to deposition of calcium in heart valves, coronary arteries, and myocardial fibers; hypertension; and cardiomyopathy. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Cardiovascular disease'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/1\">",
"      Shane, E, Dinaz, I. Hypercalcemia: Pathogenesis, clinical manifestations, differential diagnosis, and managment. In: Favus, MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. Sixth ed. Philadelphia: Lippincott, Williams, and Wilkins. 2006; 26:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/2\">",
"      Inzucchi SE. Understanding hypercalcemia. Its metabolic basis, signs, and symptoms. Postgrad Med 2004; 115:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/3\">",
"      Ohrvall U, Akerstr&ouml;m G, Ljunghall S, et al. Surgery for sporadic primary hyperparathyroidism in the elderly. World J Surg 1994; 18:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/4\">",
"      Gardner EC Jr, Hersh T. Primary hyperparathyroidism and the gastrointestinal tract. South Med J 1981; 74:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/5\">",
"      Carnaille B, Oudar C, Pattou F, et al. Pancreatitis and primary hyperparathyroidism: forty cases. Aust N Z J Surg 1998; 68:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/6\">",
"      Gaur S. Sarcoidosis manifested as hypercalcemic pancreatitis. South Med J 2001; 94:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/7\">",
"      Wynn D, Everett GD, Boothby RA. Small cell carcinoma of the ovary with hypercalcemia causes severe pancreatitis and altered mental status. Gynecol Oncol 2004; 95:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/8\">",
"      Bourgain A, Acker O, Lambaudie E, et al. [Small cell carcinoma of the ovary of the hypercalcemic type revealed by a severe acute pancreatitis: about one case]. Gynecol Obstet Fertil 2005; 33:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/9\">",
"      Mith&ouml;fer K, Fern&aacute;ndez-del Castillo C, Frick TW, et al. Acute hypercalcemia causes acute pancreatitis and ectopic trypsinogen activation in the rat. Gastroenterology 1995; 109:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/10\">",
"      Ward JB, Petersen OH, Jenkins SA, Sutton R. Is an elevated concentration of acinar cytosolic free ionised calcium the trigger for acute pancreatitis? Lancet 1995; 346:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/11\">",
"      Norton JA, Cornelius MJ, Doppman JL, et al. Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome, and multiple endocrine neoplasia type I: a prospective study. Surgery 1987; 102:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/12\">",
"      Caruana RJ, Buckalew VM Jr. The syndrome of distal (type 1) renal tubular acidosis. Clinical and laboratory findings in 58 cases. Medicine (Baltimore) 1988; 67:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/13\">",
"      Levi M, Ellis MA, Berl T. Control of renal hemodynamics and glomerular filtration rate in chronic hypercalcemia. Role of prostaglandins, renin-angiotensin system, and calcium. J Clin Invest 1983; 71:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/14\">",
"      Lins LE. Reversible renal failure caused by hypercalcemia. A retrospective study. Acta Med Scand 1978; 203:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/15\">",
"      Peacock M. Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum. J Bone Miner Res 2002; 17 Suppl 2:N87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/16\">",
"      Ahmed R, Hashiba K. Reliability of QT intervals as indicators of clinical hypercalcemia. Clin Cardiol 1988; 11:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/17\">",
"      Rosenqvist M, Nordenstr&ouml;m J, Andersson M, Edhag OK. Cardiac conduction in patients with hypercalcaemia due to primary hyperparathyroidism. Clin Endocrinol (Oxf) 1992; 37:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/18\">",
"      Kiewiet RM, Ponssen HH, Janssens EN, Fels PW. Ventricular fibrillation in hypercalcaemic crisis due to primary hyperparathyroidism. Neth J Med 2004; 62:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/19\">",
"      Diercks DB, Shumaik GM, Harrigan RA, et al. Electrocardiographic manifestations: electrolyte abnormalities. J Emerg Med 2004; 27:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/20\">",
"      Nishi SP, Barbagelata NA, Atar S, et al. Hypercalcemia-induced ST-segment elevation mimicking acute myocardial infarction. J Electrocardiol 2006; 39:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/21\">",
"      Turhan S, Kilickap M, Kilinc S. ST segment elevation mimicking acute myocardial infarction in hypercalcaemia. Heart 2005; 91:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/22\">",
"      Ashizawa N, Arakawa S, Koide Y, et al. Hypercalcemia due to vitamin D intoxication with clinical features mimicking acute myocardial infarction. Intern Med 2003; 42:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/23\">",
"      Roberts WC, Waller BF. Effect of chronic hypercalcemia on the heart. An analysis of 18 necropsy patients. Am J Med 1981; 71:371.",
"     </a>",
"    </li>",
"    <li>",
"     Albright F, Reifenstein EC Jr. The Parathyroid Glands and Metabolic Bone Disease: Selected Cases, The Williams and Wilkins Company, Baltimore 1948.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/25\">",
"      Chou FF, Sheen-Chen SM, Leong CP. Neuromuscular recovery after parathyroidectomy in primary hyperparathyroidism. Surgery 1995; 117:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33669/abstract/26\">",
"      Wilson KS, Alexander S, Chisholm IA. Band keratopathy in hypercalcemia of myeloma. Can Med Assoc J 1982; 126:1314.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 832 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-04D01F2D42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_56_33669=[""].join("\n");
var outline_f32_56_33669=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEUROPSYCHIATRIC DISTURBANCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GASTROINTESTINAL ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RENAL DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nephrolithiasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CARDIOVASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MUSCULOSKELETAL SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PHYSICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/832\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/832|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/50/42795\" title=\"table 1\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21545?source=related_link\">",
"      Clinical manifestations and causes of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1338?source=related_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20934?source=related_link\">",
"      Diagnostic approach to hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19258?source=related_link\">",
"      Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/22/28007?source=related_link\">",
"      Etiology of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=related_link\">",
"      Management of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/43/17081?source=related_link\">",
"      Nephrocalcinosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/26/23973?source=related_link\">",
"      Nephrolithiasis in renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40438?source=related_link\">",
"      Renal disease in sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_56_33670="EHL sequential views";
var content_f32_56_33670=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electrohydraulic lithotripsy of a bile duct stone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 666px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sequential fluoroscopic and endoscopic views during electrohydraulic lithotripsy (EHL) for giant extrahepatic bile duct stones.",
"    <br/>",
"    (A) Giant common and left hepatic duct stones (arrows).",
"    <br/>",
"    (B) Daughter scope inserted, stone fragmentation with EHL.",
"    <br/>",
"    (C) Stone fragments being removed with a basket (white arrow), stone in the duodenal lumen (green arrow), fluoroscopic view demonstrating clearance of the stones.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Isaac Raijman, MD and Susana Escalante, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_56_33670=[""].join("\n");
var outline_f32_56_33670=null;
var title_f32_56_33671="Intestinal Entamoeba histolytica amebiasis";
var content_f32_56_33671=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intestinal Entamoeba histolytica amebiasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/56/33671/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/56/33671/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/56/33671/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/56/33671/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/56/33671/contributors\">",
"     Edward T Ryan, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/56/33671/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/56/33671/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/56/33671/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal amebiasis is caused by the protozoan Entamoeba histolytica. Most infection is asymptomatic; clinical manifestations include amebic dysentery and extraintestinal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/1\">",
"     1",
"    </a>",
"    ]. Worldwide, approximately 40 to 50 million people develop colitis or extraintestinal disease annually with 40,000 deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/2\">",
"     2",
"    </a>",
"    ]. Extraintestinal manifestations include amebic liver abscess and other more rare manifestations such as pulmonary, cardiac, or brain involvement; these are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33031?source=see_link\">",
"     \"Extraintestinal Entamoeba histolytica amebiasis\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p>",
"    There are three species of intestinal amebae with identical morphologic characteristics: E. histolytica, E. dispar, and E. moshkovskii [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/3\">",
"     3",
"    </a>",
"    ]. E. dispar and E. moshkovskii are non-pathogenic and do not cause clinical disease; all symptomatic disease is caused by E. histolytica. Alternative diagnostics based on the genetic, antigenic, biochemical, and pathogenic differences between the three species have been developed to help differentiate between them in clinical specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/0/10243?source=see_link\">",
"     \"Nonpathogenic enteric protozoa\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H6\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17143399\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amebiasis occurs worldwide; the prevalence is disproportionately increased in developing countries because of poor socioeconomic conditions and sanitation levels. Infection with E. dispar and E. moshkovskii occurs approximately ten times more frequently than infection with E. histolytica [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Areas with high rates of amebic infection include India, Africa, Mexico, and parts of Central and South America. The overall prevalence of amebic infection may be as high as 50 percent in some areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/3\">",
"     3",
"    </a>",
"    ]. The seroprevalence of E. histolytica in one Mexican study was 8.4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/5\">",
"     5",
"    </a>",
"    ]. In another series from urban Bangladesh, children had a 4.2 percent prevalence rate of E. histolytica infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In developed countries, amebiasis is generally seen in migrants from and travelers to endemic areas. E. histolytica is not a common cause of travelers' diarrhea, and gastrointestinal infection is uncommon in travelers who have spent less than one month in endemic areas. In one prospective study of German travelers to the tropics, only 0.3 percent had pathogenic E. histolytica infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/7\">",
"     7",
"    </a>",
"    ]. Institutionalized patients and sexually-active homosexuals are also at increased risk of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States and Europe, homosexual males are principally colonized with nonpathogenic E. dispar; in these regions, HIV-infected patients are not at increased risk for intestinal or extraintestinal amebiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. In Japan and Taiwan, however, E. histolytica is much more prevalent amongst male homosexuals. Invasive, extraintestinal amebiasis (eg, hepatic abscesses) are more frequent in HIV-infected patients in these countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/3,10\">",
"     3,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17143536\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parasite exists in two forms, a cyst stage (the infective form), and a trophozoite stage (the form that causes invasive disease) (",
"    <a class=\"graphic graphic_figure graphicRef69977 \" href=\"mobipreview.htm?24/7/24696\">",
"     figure 1",
"    </a>",
"    ). Infection occurs following ingestion of amebic cysts; this is usually via contaminated food or water but can be associated with venereal transmission through fecal-oral contact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cysts can remain viable in the environment for weeks to months, and ingestion of a single cyst is sufficient to cause disease. The cysts pass through the stomach to the small intestine where they excyst to form trophozoites. The trophozoites can invade and penetrate the mucous barrier of the colon causing tissue destruction and increased intestinal secretion, and can thereby ultimately lead to bloody diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The host-parasite interaction is complex, and the virulence of different strains of E. histolytica is variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Colitis results after penetration of the trophozoite through the intestinal mucous layer, which otherwise acts as a barrier to invasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/1\">",
"     1",
"    </a>",
"    ]. The trophozoite is able to kill both epithelial cells and inflammatory cells, which is thought to occur through a number of different mechanisms including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Secretion of proteinases by the trophozoites",
"     </li>",
"     <li>",
"      Lysis of target cells via a contact-dependent mechanism",
"     </li>",
"     <li>",
"      Killing of mammalian cells by apoptosis (programmed cell death)",
"     </li>",
"     <li>",
"      Formation of amebapores, a family of small peptides that can form pores in lipid bilayers, resulting in cytolysis of infected cells",
"     </li>",
"     <li>",
"      Changes in intestinal permeability, probably via disruption of tight-junction proteins",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathogenicity of amebic trophozoites is facilitated by adherence to colonic epithelial cells via a specific lectin (the",
"    <span class=\"nowrap\">",
"     galactose/N-acetylgalactosamine",
"    </span>",
"    lectin) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/13\">",
"     13",
"    </a>",
"    ]. Mammalian cells without N-terminal galactose or N-acetylgalactosamine residues are resistant to adherence by amebic trophozoites, which is consistent with an important role for the lectin in adhesion. This lectin also plays a role in immunity, since mucosal immunity against the lectin seems to mediate some degree of protection from invasive disease following colonization. One study from Bangladesh showed that children with a mucosal IgA response against the lectin had 86 percent fewer new infections during a one year period than children without this response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/14\">",
"     14",
"    </a>",
"    ], and when reinfected had a lower incidence of infection and disease over a four year follow-up period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/15\">",
"     15",
"    </a>",
"    ]. Other amebic molecules such as lipophosphopeptidoglycan, peroxiredoxin, arginase, and lysine, and glutamic acid-rich proteins are also implicated in the pathogenesis of amoebiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of entamoeba infections are asymptomatic; this includes 90 percent of E. histolytica infections and all E. dispar infection and E. moshkovskii infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/3\">",
"     3",
"    </a>",
"    ]. Factors that influence whether infection leads to asymptomatic or invasive disease include the E. histolytica strain and host factors such as genetic susceptibility, age, and immune status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/3,17\">",
"     3,17",
"    </a>",
"    ]. Risk factors for severe disease and increased mortality include young age, pregnancy, corticosteroid treatment, malignancy, malnutrition, and alcoholism.",
"   </p>",
"   <p>",
"    Clinical amebiasis generally has a subacute onset, usually over one to three weeks. Symptoms range from mild diarrhea to severe dysentery-producing abdominal pain (12 to 80 percent), diarrhea (94 to 100 percent), and bloody stools (94 to 100 percent) to fulminant amoebic colitis. Weight loss occurs in about half of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/18\">",
"     18",
"    </a>",
"    ]. Fever occurs in 8 to 38 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/19\">",
"     19",
"    </a>",
"    ]. Amebic dysentery is diarrhea with visible blood and mucus in stools and the presence of hematophagous trophozoites (trophozoites with ingested red blood cells) in stools or tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/20\">",
"     20",
"    </a>",
"    ]. Fulminant colitis with bowel necrosis leading to perforation and peritonitis has been observed in approximately 0.5 percent of cases; associated mortality rate is more than 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/21\">",
"     21",
"    </a>",
"    ]. Toxic megacolon can also develop.",
"   </p>",
"   <p>",
"    Amebic colitis has been recognized in asymptomatic patients. Among 5193 asymptomatic individuals in Japan undergoing colonoscopy for evaluation of positive fecal occult blood tests, for example, four were found to have amebic ulcerative lesions in the cecum or ascending colon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, intestinal amebiasis may present as a chronic syndrome of diarrhea, weight loss, and abdominal pain without dysentery, lasting for years and mimicking inflammatory bowel disease. &nbsp;",
"   </p>",
"   <p>",
"    Uncommonly, localized colonic infection resulting in a mass of granulation tissue forming an ameboma can occur, mimicking colon cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Patients with amebomas usually are found to have a tender palpable mass. Other rare complications of amebiasis include perianal cutaneous amebiasis and rectovaginal fistulae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic techniques include microscopy, antigen detection, serology, molecular techniques, and colonoscopy with histological examination. Culture techniques are limited to research settings.",
"   </p>",
"   <p>",
"    Diagnosis is best accomplished by the combination of serology or antigen testing together with identification of the parasite in stool or extraintestinal sites (such as liver abscess pus).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5026049\">",
"    <span class=\"h2\">",
"     Stool microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The demonstration of cysts or trophozoites in the stool suggests intestinal amebiasis, but microscopy cannot differentiate between E. histolytica and E. dispar or E. moshkovskii strains. In addition, microscopy requires specialized expertise and is subject to operator error [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Organism excretion can vary; a minimum of three specimens on separate days should be sent to detect 85 to 95 percent of infections. Specimens can be concentrated and stained with iodine to detect cysts. To look for trophozoites, a saline wet mount and a fresh smear stained with iron hematoxylin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Wheatley's trichrome should be performed; fixation with polyvinyl alcohol for delayed staining is often useful.",
"   </p>",
"   <p>",
"    Stool specimens are frequently positive for blood in the setting of invasive intestinal amebic disease. The presence of ingested erythrocytes is not pathognomonic for E. histolytica infection (",
"    <a class=\"graphic graphic_picture graphicRef57615 \" href=\"mobipreview.htm?22/53/23390\">",
"     picture 1",
"    </a>",
"    ); ingested erythrocytes may also be observed with E. dispar. Fecal leukocytes are not always present since white cells may be destroyed by the organisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7060717\">",
"    <span class=\"h2\">",
"     Antigen testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antigen detection is sensitive, specific, rapid, easy to perform, and can distinguish between E. histolytica and E. dispar. Stool and serum antigen detection assays that use monoclonal antibodies to bind to epitopes present on pathogenic E. histolytica strains (but not on nonpathogenic E. dispar or E. moshkovskii strains) are commercially available for diagnosis of E. histolytica infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Antigen detection kits using enzyme linked immunosorbent assay (ELISA), radioimmunoassay or immunofluorescence have been developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. Antigen detection has many advantages, including ease and rapidity of the tests, capacity to differentiate between strains, greater sensitivity than microscopy, and potential for diagnosis in early infection and in endemic areas (where serology is less useful).",
"   </p>",
"   <p>",
"    The TechLab E. histolytica stool antigen test is an ELISA test that is specific for E. histolytica. The assay detects the E. histolytica-derived",
"    <span class=\"nowrap\">",
"     Gal/GalNAc",
"    </span>",
"    lectin in stool specimen; it has a sensitivity of 87 percent and a specificity of &gt;90 percent compared with culture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/32,34,35\">",
"     32,34,35",
"    </a>",
"    ]. A study comparing the TechLab E. histolytica-specific antigen detection test with PCR assays showed comparable sensitivities when performed directly on fresh stool specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serology is a useful diagnostic tool for amebiasis. E. histolytica infection results in the development of antibodies; E. dispar infection does not. Antibodies are detectable within five to seven days of acute infection and may persist for years. Approximately 10 to 35 percent of uninfected individuals in endemic areas have anti-amebic antibodies due to previous infection with E. histolytica [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/3\">",
"     3",
"    </a>",
"    ]. Therefore, negative serology is helpful for exclusion of disease, but positive serology cannot distinguish between acute and previous infection.",
"   </p>",
"   <p>",
"    Indirect hemagglutination (IHA) is the most sensitive serologic assay; it is positive in approximately 90 percent of patients with symptomatic intestinal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/3\">",
"     3",
"    </a>",
"    ]. Agar gel diffusion and counterimmunophoresis are less sensitive than IHA but usually only remain positive for 6 to 12 months, which may make them more useful in endemic areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/36\">",
"     36",
"    </a>",
"    ]. A commercially available ELISA that has a sensitivity of 93 percent compared to IHA has also been developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Molecular methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of parasitic DNA or RNA in feces via probes can also be used to diagnose amebic infection and to differentiate between the three different strains, but these methods are primarily research tools [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polymerase chain reaction (PCR) techniques can detect E. histolytica in stool specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/33,40-42\">",
"     33,40-42",
"    </a>",
"    ]. One study showed that PCR was significantly more sensitive than either microscopy or cultures, and that it was 100 percent specific for E. histolytica [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/43\">",
"     43",
"    </a>",
"    ]. PCR is about 100 times more sensitive than fecal antigen tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of investigators have developed PCR methods for the diagnosis of intestinal amebiasis and differentiation between pathogenic and nonpathogenic amebae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. These methods are highly sensitive and specific research tools, but are generally not yet commercially available for diagnostic clinical testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Visual inspection of the colon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sigmoidoscopy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    colonoscopy can be performed either to make the diagnosis of amebiasis or to exclude other causes of the patients' symptoms. However, colonoscopy is not recommended as a routine diagnostic approach since intestinal amebic ulcerations increase the likelihood of perforation during instillation of air to expand the colon.",
"   </p>",
"   <p>",
"    Scrapings or biopsy specimens, best taken from the edge of ulcers, may be positive for cysts or trophozoites on microscopy, and antigen testing for E. histolytica may be positive. Colonic lesions in amebic dysentery range from nonspecific mucosal thickening and inflammation to classic flask-shaped amebic ulcers (",
"    <a class=\"graphic graphic_picture graphicRef66341 \" href=\"mobipreview.htm?31/12/31945\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;All E. histolytica infections should be treated, even in the absence of symptoms, given the potential risk of developing invasive disease and the risk of spread to family members [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. The goals of antibiotic therapy of intestinal amebiasis are to eliminate the invading trophozoites and to eradicate intestinal carriage of the organism.",
"   </p>",
"   <p>",
"    E. dispar and E. moshkovskii infections do not require treatment. In countries where amebic infections are endemic, asymptomatic patients incidentally found to have stools positive for amebae are frequently presumed to have infection with E.",
"    <span class=\"nowrap\">",
"     dispar/E.",
"    </span>",
"    moshkovskii and are not further evaluated or treated. As antigen tests that can differentiate between E.",
"    <span class=\"nowrap\">",
"     dispar/E.",
"    </span>",
"    moshkovskii and E. histolytica become more widely available in these countries, this practice may change.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7060848\">",
"    <span class=\"h2\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive colitis is generally managed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (alternative therapies include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    , ornidazole, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    ), followed by a luminal agent (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    , diiodohydroxyquin or diloxanide furoate) to eliminate intraluminal cysts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/2\">",
"     2",
"    </a>",
"    ]. A ten day course of metronidazole eliminates intraluminal infection in many cases, but a second agent is still warranted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/48\">",
"     48",
"    </a>",
"    ]. Asymptomatic patients with E. histolytica (and not E.",
"    <span class=\"nowrap\">",
"     dispar/E.",
"    </span>",
"    moshkovskii) should be treated with an intraluminal agent alone.",
"   </p>",
"   <p>",
"    Dosing for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    is 500 to 750 mg PO three times daily for 7 to 10 days in adults and 35 to 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in three divided doses for 7 to 10 days in children. Shorter duration of metronidazole is generally not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Metronidazole is well absorbed from the gastrointestinal tract; intravenous therapy offers no significant advantage as long as the patient can take oral medications and has no major defect in small bowel absorption. Metronidazole resistance in E. histolytica trophozoites has not been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatives to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    , ornidazole, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/49,50,52\">",
"     49,50,52",
"    </a>",
"    ]. Tinidazole (2 g PO daily for three days) has a cure rate of 90 to 93 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/49,50,53\">",
"     49,50,53",
"    </a>",
"    ]. One review showed that tinidazole resulted in greater resolution of clinical symptoms compared with metronidazole, but there was inconclusive evidence of its advantage in eradication of E. histolytica in the stools [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/20\">",
"     20",
"    </a>",
"    ]. Tinidazole is also better tolerated than metronidazole.",
"   </p>",
"   <p>",
"    Intraluminal infection can be treated with one of the following regimens:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    (25-30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally in three divided doses for seven days), diiodohydroxyquin (650 mg orally three times daily for 20 days for adults and 30-40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in three divided doses for 20 days for children), or diloxanide furoate (500 mg orally three times daily for 10 days for adults and 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in three divided doses for 10 days for children).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who have suspected or proven peritonitis, broad spectrum antibacterial therapy should be administered. Surgical intervention is required in the setting of significant bowel perforation or abscesses that fail to respond to antibiotic therapy. Toxic megacolon requires colectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of amebic infection in travelers to endemic areas involves avoidance of untreated water in endemic areas and uncooked food, such as fruit and vegetables that may have been washed in local water. Amebic cysts are resistant to chlorine at the levels used in water supplies, but disinfection with iodine may be effective. Avoiding sexual practices that may lead to fecal-oral contact is also advisable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/48/8967?source=see_link&amp;anchor=H22624013#H22624013\">",
"     \"Travel advice\", section on 'Behavioral precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Vaccine development",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence of partial acquired immunity to the organism. Protection from invasive disease has been associated with mucosal IgA antibodies to the amebic adherence lectin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. However, recurrent intestinal infection and persistent colonization does occur despite detectable antiamebic antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/54\">",
"     54",
"    </a>",
"    ]. Thus, it seems probable that acquired, but incomplete, immunity against infection occurs, and a vaccine that can reduce infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    invasive disease may therefore be feasible.",
"   </p>",
"   <p>",
"    The relative importance of systemic and mucosal, cellular and humoral immunity is unclear. Several amebic proteins associated with virulence have been identified and are being studied as potential vaccine components. Development of both parenteral and oral vaccines for humans is in progress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33671/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7061138\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intestinal amebiasis is caused by the protozoan Entamoeba histolytica. There are three species of intestinal amebae with identical morphologic characteristics: E. histolytica, E. dispar, and E. moshkovskii. E. dispar and E. moshkovskii are non-pathogenic and do not cause clinical disease; all symptomatic disease is caused by E. histolytica. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Amebiasis occurs worldwide; the prevalence is disproportionately increased in developing countries because of poor socioeconomic conditions and sanitation levels. Areas with high rates of amebic infection include India, Africa, Mexico and parts of Central and South America. In developed countries, amebiasis is generally seen in migrants from and travelers to endemic areas. (See",
"      <a class=\"local\" href=\"#H17143399\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical amebiasis generally has a subacute onset, usually over one to three weeks. Symptoms range from mild diarrhea to severe dysentery producing abdominal pain, diarrhea and bloody stools. Fulminant colitis with bowel necrosis leading to perforation and peritonitis can occur, as can toxic megacolon. Amebic colitis has been recognized in asymptomatic patients as well. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis is best accomplished by the combination of serology or antigen testing together with identification of the parasite in stool or extraintestinal sites (such as liver abscess pus). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All E. histolytica infections should be treated, even in the absence of symptoms, given the potential risk of developing invasive disease and the risk of spread to family members. The goals of antibiotic therapy of intestinal amebiasis are to eliminate the invading trophozoites and to eradicate intestinal carriage of the organism. We suggest treatment of invasive colitis with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/14/5349?source=see_link\">",
"       tinidazole",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest subsequent treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16099?source=see_link\">",
"       paromomycin",
"      </a>",
"      to eliminate intraluminal cysts (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Dosing is outlined above. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prevention of amebic infection in travelers to endemic areas involves avoidance of untreated water in endemic areas and uncooked food, such as fruit and vegetables, that may have been washed in local water. Amebic cysts are resistant to chlorine at the levels used in water supplies, but disinfection with iodine may be effective. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/1\">",
"      Haque R, Huston CD, Hughes M, et al. Amebiasis. N Engl J Med 2003; 348:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/2\">",
"      Li E, Stanley SL Jr. Protozoa. Amebiasis. Gastroenterol Clin North Am 1996; 25:471.",
"     </a>",
"    </li>",
"    <li>",
"     Petri, WA, Singh, U. Enteric Amebiasis. In: Tropical Infectious Diseases: Principles, pathogens, and practice. Second edition, Guerrant, R, Walker, DH, Weller, PF (eds). Elsevier, Philadelphia 2006. p. 967.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/4\">",
"      Petri WA Jr, Jackson TF, Gathiram V, et al. Pathogenic and nonpathogenic strains of Entamoeba histolytica can be differentiated by monoclonal antibodies to the galactose-specific adherence lectin. Infect Immun 1990; 58:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/5\">",
"      Caballero-Salcedo A, Viveros-Rogel M, Salvatierra B, et al. Seroepidemiology of amebiasis in Mexico. Am J Trop Med Hyg 1994; 50:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/6\">",
"      Haque R, Faruque AS, Hahn P, et al. Entamoeba histolytica and Entamoeba dispar infection in children in Bangladesh. J Infect Dis 1997; 175:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/7\">",
"      Weinke T, Friedrich-J&auml;nicke B, Hopp P, Janitschke K. Prevalence and clinical importance of Entamoeba histolytica in two high-risk groups: travelers returning from the tropics and male homosexuals. J Infect Dis 1990; 161:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/8\">",
"      Salit IE, Khairnar K, Gough K, Pillai DR. A possible cluster of sexually transmitted Entamoeba histolytica: genetic analysis of a highly virulent strain. Clin Infect Dis 2009; 49:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/9\">",
"      Mor&aacute;n P, Ramos F, Ramiro M, et al. Infection by human immunodeficiency virus-1 is not a risk factor for amebiasis. Am J Trop Med Hyg 2005; 73:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/10\">",
"      Hung CC, Deng HY, Hsiao WH, et al. Invasive amebiasis as an emerging parasitic disease in patients with human immunodeficiency virus type 1 infection in Taiwan. Arch Intern Med 2005; 165:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/11\">",
"      Padilla-Vaca F, Anaya-Vel&aacute;zquez F. Insights into Entamoeba histolytica virulence modulation. Infect Disord Drug Targets 2010; 10:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/12\">",
"      Mortimer L, Chadee K. The immunopathogenesis of Entamoeba histolytica. Exp Parasitol 2010; 126:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/13\">",
"      Stanley SL Jr. Amoebiasis. Lancet 2003; 361:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/14\">",
"      Haque R, Duggal P, Ali IM, et al. Innate and acquired resistance to amebiasis in bangladeshi children. J Infect Dis 2002; 186:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/15\">",
"      Haque R, Mondal D, Duggal P, et al. Entamoeba histolytica infection in children and protection from subsequent amebiasis. Infect Immun 2006; 74:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/16\">",
"      Lejeune M, Rybicka JM, Chadee K. Recent discoveries in the pathogenesis and immune response toward Entamoeba histolytica. Future Microbiol 2009; 4:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/17\">",
"      Xim&eacute;nez C, Mor&aacute;n P, Rojas L, et al. Reassessment of the epidemiology of amebiasis: state of the art. Infect Genet Evol 2009; 9:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/18\">",
"      Petri WA Jr. Recent advances in amebiasis. Crit Rev Clin Lab Sci 1996; 33:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/19\">",
"      Adams EB, MacLeod IN. Invasive amebiasis. I. Amebic dysentery and its complications. Medicine (Baltimore) 1977; 56:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/20\">",
"      Gonzales ML, Dans LF, Martinez EG. Antiamoebic drugs for treating amoebic colitis. Cochrane Database Syst Rev 2009; :CD006085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/21\">",
"      Aristiz&aacute;bal H, Acevedo J, Botero M. Fulminant amebic colitis. World J Surg 1991; 15:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/22\">",
"      Okamoto M, Kawabe T, Ohata K, et al. Amebic colitis in asymptomatic subjects with positive fecal occult blood test results: clinical features different from symptomatic cases. Am J Trop Med Hyg 2005; 73:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/23\">",
"      Stockinger ZT. Colonic ameboma: its appearance on CT: report of a case. Dis Colon Rectum 2004; 47:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/24\">",
"      Misra SP, Misra V, Dwivedi M. Ileocecal masses in patients with amebic liver abscess: etiology and management. World J Gastroenterol 2006; 12:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/25\">",
"      Kenner BM, Rosen T. Cutaneous amebiasis in a child and review of the literature. Pediatr Dermatol 2006; 23:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/26\">",
"      Rayan HZ. Microscopic overdiagnosis of intestinal amoebiasis. J Egypt Soc Parasitol 2005; 35:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/27\">",
"      Abd-Alla MD, Jackson TF, Gathiram V, et al. Differentiation of pathogenic Entamoeba histolytica infections from nonpathogenic infections by detection of galactose-inhibitable adherence protein antigen in sera and feces. J Clin Microbiol 1993; 31:2845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/28\">",
"      Gonzalez-Ruiz A, Haque R, Rehman T, et al. A monoclonal antibody for distinction of invasive and noninvasive clinical isolates of Entamoeba histolytica. J Clin Microbiol 1992; 30:2807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/29\">",
"      Gonz&aacute;lez-Ru&iacute;z A, Haque R, Rehman T, et al. Further diagnostic use of an invasive-specific monoclonal antibody against Entamoeba histolytica. Arch Med Res 1992; 23:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/30\">",
"      Haque R, Neville LM, Hahn P, Petri WA Jr. Rapid diagnosis of Entamoeba infection by using Entamoeba and Entamoeba histolytica stool antigen detection kits. J Clin Microbiol 1995; 33:2558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/31\">",
"      Gonzalez-Ruiz A, Haque R, Rehman T, et al. Diagnosis of amebic dysentery by detection of Entamoeba histolytica fecal antigen by an invasive strain-specific, monoclonal antibody-based enzyme-linked immunosorbent assay. J Clin Microbiol 1994; 32:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/32\">",
"      Haque R, Kress K, Wood S, et al. Diagnosis of pathogenic Entamoeba histolytica infection using a stool ELISA based on monoclonal antibodies to the galactose-specific adhesin. J Infect Dis 1993; 167:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/33\">",
"      Haque R, Ali IK, Akther S, Petri WA Jr. Comparison of PCR, isoenzyme analysis, and antigen detection for diagnosis of Entamoeba histolytica infection. J Clin Microbiol 1998; 36:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/34\">",
"      Petri WA Jr, Singh U. Diagnosis and management of amebiasis. Clin Infect Dis 1999; 29:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/35\">",
"      Haque R, Petri WA Jr. Diagnosis of amebiasis in Bangladesh. Arch Med Res 2006; 37:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/36\">",
"      Patterson M, Healy GR, Shabot JM. Serologic testing for amoebiasis. Gastroenterology 1980; 78:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/37\">",
"      Rosenblatt JE, Sloan LM, Bestrom JE. Evaluation of an enzyme-linked immunoassay for the detection in serum of antibodies to Entamoeba histolytica. Diagn Microbiol Infect Dis 1995; 22:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/38\">",
"      Garfinkel LI, Giladi M, Huber M, et al. DNA probes specific for Entamoeba histolytica possessing pathogenic and nonpathogenic zymodemes. Infect Immun 1989; 57:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/39\">",
"      Bracha R, Diamond LS, Ackers JP, et al. Differentiation of clinical isolates of Entamoeba histolytica by using specific DNA probes. J Clin Microbiol 1990; 28:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/40\">",
"      Tachibana H, Ihara S, Kobayashi S, et al. Differences in genomic DNA sequences between pathogenic and nonpathogenic isolates of Entamoeba histolytica identified by polymerase chain reaction. J Clin Microbiol 1991; 29:2234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/41\">",
"      Roy S, Kabir M, Mondal D, et al. Real-time-PCR assay for diagnosis of Entamoeba histolytica infection. J Clin Microbiol 2005; 43:2168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/42\">",
"      Qvarnstrom Y, James C, Xayavong M, et al. Comparison of real-time PCR protocols for differential laboratory diagnosis of amebiasis. J Clin Microbiol 2005; 43:5491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/43\">",
"      Blessmann J, Buss H, Nu PA, et al. Real-time PCR for detection and differentiation of Entamoeba histolytica and Entamoeba dispar in fecal samples. J Clin Microbiol 2002; 40:4413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/44\">",
"      Fotedar R, Stark D, Beebe N, et al. Laboratory diagnostic techniques for Entamoeba species. Clin Microbiol Rev 2007; 20:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/45\">",
"      Tanyuksel M, Petri WA Jr. Laboratory diagnosis of amebiasis. Clin Microbiol Rev 2003; 16:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/46\">",
"      Hamzah Z, Petmitr S, Mungthin M, et al. Development of multiplex real-time polymerase chain reaction for detection of Entamoeba histolytica, Entamoeba dispar, and Entamoeba moshkovskii in clinical specimens. Am J Trop Med Hyg 2010; 83:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/47\">",
"      Liang SY, Hsia KT, Chan YH, et al. Evaluation of a new single-tube multiprobe real-time PCR for diagnosis of Entamoeba histolytica and Entamoeba dispar. J Parasitol 2010; 96:793.",
"     </a>",
"    </li>",
"    <li>",
"     Drugs for Parasitic Infections, 2nd Ed, The Medical Letter, Inc, New Rochelle, NY 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/49\">",
"      Misra NP, Gupta RC. A comparison of a short course of single daily dosage therapy of tinidazole with metronidazole in intestinal amoebiasis. J Int Med Res 1977; 5:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/50\">",
"      Singh G, Kumar S. Short course of single daily dosage treatment with tinidazole and metronidazole in intestinal amoebiasis: a comparative study. Curr Med Res Opin 1977; 5:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/51\">",
"      Ravdin JI, Skilogiannis J. In vitro susceptibilities of Entamoeba histolytica to azithromycin, CP-63,956, erythromycin, and metronidazole. Antimicrob Agents Chemother 1989; 33:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/52\">",
"      Rossignol JF, Kabil SM, El-Gohary Y, Younis AM. Nitazoxanide in the treatment of amoebiasis. Trans R Soc Trop Med Hyg 2007; 101:1025.",
"     </a>",
"    </li>",
"    <li>",
"     Presutti antiprotozoal agent Tindamax clears FDA; AWP is $18 per dose. In: \"The Pink Sheet\" vol 66, F-D-C Reports, Inc. Chevy Chase, MD 2004. p.10.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/54\">",
"      Stanley SL Jr. Protective immunity to amebiasis: new insights and new challenges. J Infect Dis 2001; 184:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33671/abstract/55\">",
"      Lotter H, Tannich E. The current status of an amebiasis vaccine. Arch Med Res 2006; 37:292.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5727 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9F1D191359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_56_33671=[""].join("\n");
var outline_f32_56_33671=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7061138\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17143399\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17143536\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5026049\">",
"      Stool microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7060717\">",
"      Antigen testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Molecular methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Visual inspection of the colon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7060848\">",
"      Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Peritonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Vaccine development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7061138\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5727\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5727|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/7/24696\" title=\"figure 1\">",
"      Amebiasis life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5727|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/53/23390\" title=\"picture 1\">",
"      Entamoeba histolytica trophozoite",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/12/31945\" title=\"picture 2\">",
"      Ulceration in amebic colitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33031?source=related_link\">",
"      Extraintestinal Entamoeba histolytica amebiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/0/10243?source=related_link\">",
"      Nonpathogenic enteric protozoa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/48/8967?source=related_link\">",
"      Travel advice",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_56_33672="Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins";
var content_f32_56_33672=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/56/33672/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/56/33672/contributors\">",
"     Wendell F Rosse, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/56/33672/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/56/33672/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/56/33672/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/56/33672/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/56/33672/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/56/33672/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cold agglutinin disease is typically characterized by the presence of IgM antibodies (rarely IgA or IgG) directed against polysaccharide antigens on the red blood cell surface. The most common cold agglutinins are designated anti-I; they react best with untreated adult red cells. Others that react best with fetal or cord red cells are called anti-i. Much less common are antibodies that do not react with enzymatically-treated red cells (eg, anti-Pr). Rarely, patients are seen with IgG cold-reacting antibodies, either alone or in combination with IgM cold-reacting antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30535?source=see_link\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the clinical manifestations, diagnosis, and treatment of autoimmune hemolytic anemia (AIHA) due to cold agglutinins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/2\">",
"     2",
"    </a>",
"    ]. Paroxysmal cold hemoglobinuria, another form of cold-related hemolysis, as well as the clinical features and treatment of AIHA due to warm agglutinins are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/2/16422?source=see_link\">",
"     \"Paroxysmal cold hemoglobinuria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19256?source=see_link\">",
"     \"Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/62/14313?source=see_link\">",
"     \"Treatment of autoimmune hemolytic anemia: Warm agglutinins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic cold agglutinins are produced either in response to infection or by paraneoplastic or neoplastic growth of a single immunocyte clone. In either case, they generally share the same immunochemical characteristics and polysaccharide specificities, and result in the same clinical manifestations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cold agglutinin AIHA may have symptoms related to both the anemia and the agglutination of red blood cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of anemia include exertional dyspnea, dyspnea at rest, varying degrees of fatigue, and signs and symptoms of the hyperdynamic state; the intensity of these symptoms varies with both the degree and rapidity of the fall in hematocrit. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=see_link&amp;anchor=H11#H11\">",
"     \"Approach to the adult patient with anemia\", section on 'Clinical consequences'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Changes on exposure to cold",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cold agglutinin syndrome may also have symptoms related to the agglutination of red cells in vivo upon exposure to cold ambient temperatures. The most common manifestations of this process are livedo reticularis (",
"    <a class=\"graphic graphic_picture graphicRef61212 \" href=\"mobipreview.htm?9/55/10101\">",
"     picture 1",
"    </a>",
"    ) and acrocyanosis, a dark, purple to gray discoloration of the skin on the most acral parts &mdash; finger tips, toes, nose, and ears. These changes disappear upon warming of the part and there is little or no reactive hyperemia, as occurs in the Raynaud phenomenon. This process may be sufficiently severe to cause ulceration of the skin.",
"   </p>",
"   <p>",
"    Acral discoloration can be reproduced by placing the patient's hand in tepid water to which ice is",
"    <strong>",
"     slowly",
"    </strong>",
"    added. The hand should not be placed directly into very cold water, since this can produce enough arterial vasospasm to lower the blood flow without agglutination.",
"   </p>",
"   <p>",
"    Patients may also complain of pain and discomfort on swallowing cold food or liquids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Other physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cold agglutinin disease also may have scleral icterus and an enlarged spleen from the resulting hemolysis. If enlarged lymph nodes are present, an underlying lymphoma should be suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Benign chronic cold agglutinin syndrome and malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions associated with cold agglutinins appear to be part of a spectrum that ranges from \"benign\" cold agglutinin disease to high-grade malignant lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. In one series of 78 patients with persistent cold agglutinins, 28 had chronic cold agglutinin disease, 6 had chronic lymphocytic leukemia, 31 had lymphoma, and 13 had Waldenstrom macroglobulinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic cold agglutinin syndrome is due to a \"benign\" monoclonal IgM gammopathy which usually occurs in persons &gt;60 years of age. The antibody is nearly always anti-I in specificity and characterized by bearing kappa light chains (ie, IgM kappa). In many patients, it persists without change for many years. However, in 5 to 10 percent of patients who present with chronic cold agglutinin syndrome, a malignant clone arises that expresses the cold agglutinin. This may be heralded by an increasing titer of the antibody, even before the other manifestations of the disease (eg, enlarged lymph nodes, circulating malignant lymphocytes) may be manifest. The presence of trisomy 3 on chromosomal analysis of the lymphocytes may predict for this transformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with lymphoid malignancy, those with the most indolent variants (chronic lymphocytic leukemia, small lymphocytic lymphoma) may have antibodies with specificity for the I antigen, whereas those with the more aggressive forms are more likely to have antibodies with specificity for the i antigen. There are exceptions to this rule but the finding of an anti-i antibody in the absence of viral disease is usually a clear indication that the patient is harboring a lymphoma.",
"   </p>",
"   <p>",
"    Whenever the cold agglutinin is the result of malignant proliferation, its concentration in the plasma may be used as a tumor marker. The antibody may disappear with appropriate treatment and reappear with relapse of the tumor.",
"   </p>",
"   <p>",
"    Monoclonal cold agglutinins, usually anti-I in specificity and bearing kappa light chains, may occur in patients with nonlymphocytic tumors, particularly adenocarcinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/10\">",
"     10",
"    </a>",
"    ]. The age of the patients with such tumors usually corresponds to the time of highest natural incidence of cold agglutinins (age &gt;60); as a result, it is not certain whether the two conditions occur randomly or are related.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cold agglutinins regularly occur during the course of two infections, Mycoplasma pneumoniae (primary atypical pneumonia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/11\">",
"     11",
"    </a>",
"    ] and infectious mononucleosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/12\">",
"     12",
"    </a>",
"    ]. In the former, they are usually specific for the I antigen and in the latter, the i antigen (",
"    <a class=\"graphic graphic_table graphicRef61974 \" href=\"mobipreview.htm?25/58/26540\">",
"     table 1",
"    </a>",
"    ). Although low titers of these antibodies are frequently encountered in patients with these disorders, clinical manifestations of cold agglutinin syndrome occur only in those unusual cases where the antibody titer is greatly elevated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31018?source=see_link\">",
"     \"Infectious mononucleosis in adults and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/5/3162?source=see_link&amp;anchor=H9#H9\">",
"     \"Mycoplasma pneumoniae infection in adults\", section on 'Hemolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less commonly, cold agglutinins are associated with other viral diseases, such as cytomegalovirus and varicella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/13\">",
"     13",
"    </a>",
"    ]. One bacterial infection, a particular strain of Listeria monocytogenes, may also cause the production of anti-I antibodies because of shared epitopes on its surface.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anemia of cold agglutinin disease is highly variable but is usually not severe, and is mainly due to extravascular hemolysis. In some cases, however, an IgG antibody accompanies the cold agglutinin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/14\">",
"     14",
"    </a>",
"    ]. The hemolysis may be greater and the anemia more severe in these patients. In severe cases, hemolysis may also be intravascular. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30535?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease\", section on 'Pathophysiology of RBC destruction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Great care must be taken in analyzing the blood on flow cytometry. Cold agglutinins, activated by a fall in temperature either in the sample prior to counting or during cooling of the sample within the apparatus itself, will cause red blood cells to pass through the counter in small groups, rather than one by one, and will be counted as macrocytic cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/15\">",
"     15",
"    </a>",
"    ]. This problem is sufficiently common that spurious macrocytosis should be considered a clue to the possible presence of cold agglutinins. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/16/21767?source=see_link&amp;anchor=H14#H14\">",
"     \"Macrocytosis\", section on 'Spurious macrocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are two general ways to determine that these sorts of artifact have occurred. First, examination of the peripheral smear (or alternatively of a cooled RBC suspension) may confirm RBC agglutination (",
"    <a class=\"graphic graphic_picture graphicRef50522 \" href=\"mobipreview.htm?15/10/15527\">",
"     picture 2",
"    </a>",
"    ). Second, examination of the erythrocyte volume histograms as printed out by the automated counter may show that populations of RBCs are present with an MCV two to three times that of the patient's normal RBC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/16\">",
"     16",
"    </a>",
"    ]. These abnormal populations should disappear on warming of the sample if cold agglutinins are present. This artifact can be avoided if the blood is thoroughly warmed before analysis.",
"   </p>",
"   <p>",
"    The reticulocyte count is often elevated. On occasion, the increase may be less than one would expect for the degree of anemia, suggesting the additional presence of marrow suppression (eg, infection, malignancy, chemotherapy) or concomitant nutrient deficiency (eg, iron, folate, B12). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18489?source=see_link&amp;anchor=H25#H25\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\", section on 'Hemolysis without reticulocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The bone marrow usually shows erythroid hyperplasia and the presence of lymphoplasmacytic aggregates. The latter are often nearly monoclonal on analysis and consist of cells that are making the antibody. When lymphoma supervenes, the aggregates may become larger and confluent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antiglobulin (Coombs) test",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the antiglobulin (Coombs') test, the RBCs of the patient are washed free of adherent proteins and reacted with antiserum or monoclonal antibodies prepared against the various immunoglobulins and a fragment of the third component of complement, C3d. This test is invariably positive using anti-C3 and is usually negative with anti-IgG (",
"    <a class=\"graphic graphic_table graphicRef69817 \" href=\"mobipreview.htm?38/6/39020\">",
"     table 2",
"    </a>",
"    ). However, when an IgG antibody accompanies the cold agglutinin, the test may be positive with anti-IgG as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cold agglutinins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Great care must taken in collecting blood for cold agglutinin titration; the specimen must be maintained at 37 to 40&ordm;C until the clot has formed and retracted and the serum has been removed.",
"   </p>",
"   <p>",
"    The titer of cold agglutinin in the serum (ie, the highest dilution of the serum sample at which agglutination of red cells in the cold is still seen) is highly variable among affected patients, but is usually quite constant for a given patient. Cold agglutinins are typically present in normal individuals in low titer (less than 1 in 40 in virtually all normal subjects, and usually less than 1 in 10). The titer in patients with cold agglutinin syndrome may range as high as 1 in 50,000 or more. Hemolysis is seldom seen if the titer is less than 1 in 1000.",
"   </p>",
"   <p>",
"    In addition to the concentration of antibody, the amount of hemolysis also depends upon other factors, including the thermal amplitude of the interaction (ie, the highest temperature at which antibody and antigen are able to interact), inhibition of antibody binding by cell bound C3, and the presence of hexameric IgM antibodies. Some cold agglutinins are cryoprecipitable; these antibodies generally fix C1 poorly. Rare cold agglutinins are IgA and do not fix C1 at all.",
"   </p>",
"   <p>",
"    When cold agglutinin production is secondary to Mycoplasma infection or infectious mononucleosis, it usually occurs about two weeks after the onset of the primary disease. Peak antibody titers are quickly reached and diminish as soon as the illness begins to resolve. The titer is usually back to normal three to four months after the initial occurrence. The manifestations of the primary disease often predominate, although hemolysis can be significant in some cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/5/3162?source=see_link&amp;anchor=H14#H14\">",
"     \"Mycoplasma pneumoniae infection in adults\", section on 'Laboratory abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of cold agglutinin disease is made when the following are present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Presence of a high titer of cold agglutinins. While the upper limit of normal is 1 in 40, hemolysis is not usually seen unless titers are above 1 in 1000. The typical patient with cold agglutinin disease has a titer in excess of 1 in 10,000.",
"     </li>",
"     <li>",
"      Positive direct antiglobulin (Coombs) test for the presence of bound complement on red cells. The test is usually negative for bound IgG.",
"     </li>",
"     <li>",
"      The additional diagnosis of mycoplasma infection, infectious mononucleosis, or lymphoma should be made under appropriate clinical circumstances (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a high titer of cold agglutinins and a positive Coombs test for bound complement are both present, the differential diagnosis is limited:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paroxysmal cold hemoglobinuria is associated with an IgG antibody, usually with anti-P specificity, a positive Donath-Landsteiner test, and, frequently, a recent history of a viral infection. The Coombs test may be positive for bound complement, but the \"cold agglutinin\" titer is, at most, only moderately elevated (ie, &lt;1:160). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/2/16422?source=see_link\">",
"       \"Paroxysmal cold hemoglobinuria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug-induced autoimmune hemolytic anemia may be associated with a positive Coombs test for bound complement. A positive drug history and lack of elevated cold agglutinins should help to make this diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/2/20521?source=see_link\">",
"       \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A history of symptoms induced by exposure to cold may be present in patients with cryoglobulinemia or the Raynaud phenomenon. However, the Coombs test is usually negative and cold agglutinins are not increased. Rarely, cold agglutinins may be cold-precipitable (cryoglobulin); in such patients, acral necrosis is sometimes seen, but hemolysis is often less than expected for the titer of antibody. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22522?source=see_link\">",
"       \"Overview of cryoglobulins and cryoglobulinemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6921?source=see_link\">",
"       \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SPECIAL PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special precautions need to be taken for the patient with cold agglutinins in order to avoid the consequences of exposure to cold temperatures.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ideally, all patients in whom hypothermic surgical procedures are contemplated should be routinely tested preoperatively for the presence of cold agglutinins. Exposure of large blood-containing areas to cold temperatures may result in marked hemolysis and other complications unless precautions are taken [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/17\">",
"       17",
"      </a>",
"      ]. Appropriate changes in cardiopulmonary bypass and myocardial management plans should be made in patients who test positive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/18\">",
"       18",
"      </a>",
"      ]. As examples, the patient may undergo plasmapheresis just prior to surgery (carefully performed to avoid exposure to cold), and forced warm air may be used on the operative field [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Plasmapheresis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Space heaters may be necessary to keep room temperature at adequate levels.",
"     </li>",
"     <li>",
"      Intravenous solutions and previously refrigerated blood products must have their temperature raised before infusion. Warming coils for such use are commercially available. Red cell preparations should not be heated above 40&ordm;C, as thermal hemolysis may ensue. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42214?source=see_link&amp;anchor=H5#H5\">",
"       \"Transfusion reactions caused by chemical and physical agents\", section on 'Blood warmers'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Use of cooling blankets to reduce fever in patients with cold agglutinins may result in worsening of hemolysis as well as peripheral gangrene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Worsening hemolysis can occur if a complement-depleted patient is transfused with plasma-containing (ie, complement-containing) blood products [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/21\">",
"       21",
"      </a>",
"      ]. Accordingly, if red cell transfusion is required, washed red cell preparations should be employed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Avoidance of cold",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most useful single therapy in cold agglutinin disease is avoidance of cold. This means that the patient must dress warmly even in the summer. Warm shoes, stockings, and gloves are essential and many patients use a face scarf, ear muffs, warm hats, and other clothing to maintain warmth. If possible, patients living in northern climes should try to live the coldest months in more temperate regions. Avoidance of cold demands constant vigilance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cytotoxic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytotoxic agents, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , have been given to reduce the production of antibody. While sometimes successful in combination with corticosteroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/22\">",
"     22",
"    </a>",
"    ], this modality is not generally useful, since the therapeutic index is too narrow. However, when the patient has an underlying lymphoma, appropriately aggressive chemotherapy is indicated, which will treat the cold agglutinin disease, as well. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Benign chronic cold agglutinin syndrome and malignancy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of reports have indicated the usefulness of the monoclonal anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , alone or in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    , in the treatment of subjects with cold agglutinin disease and severe hemolysis not responding to treatment with conventional therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/2,23-28\">",
"     2,23-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an uncontrolled prospective study, 14 of 27 patients with cold agglutinin disease, 15 of whom had been previously treated, responded to a single course of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV on days 1, 8, 15, and 22), and 6 of 10 responded to re-treatment with this agent plus interferon (rituximab as per first course plus interferon 5 million units SQ three times per week starting two weeks before retreatment with rituximab) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/29\">",
"       29",
"      </a>",
"      ]. The overall response rate was 54 percent. The median increase in hemoglobin levels in responders was 4.0",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      with median times to response and duration of response of 1.5 and 11 months, respectively. Treatment was well-tolerated; response could not be predicted using pretreatment hematologic, immunologic, or histologic parameters.",
"     </li>",
"     <li>",
"      In a second uncontrolled prospective study, 22 of 29 patients with symptomatic cold agglutinin disease, 10 of whom were previously unresponsive to treatment with single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , responded to a combination of intravenous rituximab (375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1, 29, 57, and 85) plus oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 through 5, 29 through 34, 57 through 61, and 85 through 89) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/30\">",
"       30",
"      </a>",
"      ]. Complete and overall response rates were 21 and 76 percent, respectively, with an estimated median response duration in excess of 66 months. Grade 4 hematologic toxicity (absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &lt;500/microL)",
"      </span>",
"      occurred in four patients. Dose reduction or discontinuation of fludarabine occurred in 13 patients (45 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A prospective study investigated the efficacy, safety, and response duration of",
"    <strong>",
"     reduced",
"    </strong>",
"    doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (100 mg fixed dose weekly for four doses) along with a short course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (initial dose 1",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for 30 days, with a slow taper thereafter) as primary (eight) or secondary (one) therapy in nine patients with cold AIHA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/31\">",
"     31",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After two months of treatment, complete responses (ie, hemoglobin &gt;12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      with normalization of all hemolytic markers) and partial responses (ie, hemoglobin 10 to 12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or at least a 2",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      increase from baseline with no transfusion requirement) were noted in four and one subjects, respectively, for an overall response rate of 56 percent.",
"     </li>",
"     <li>",
"      Complete plus partial response rates were 78 and 50 percent at 6 and 12 months, respectively, with relapse rates of 11 and 33 percent, respectively. The estimated two-year relapse-free survival was 40 percent.",
"     </li>",
"     <li>",
"      Treatment was well tolerated; no patient experienced the most frequently described infusion-related reactions from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and no infectious, hematologic, or extra-hematologic complications were seen during a median follow-up period of 15 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Better results were obtained when this regimen was used in patients with warm AIHA. Additional experience will be needed before this regimen can be recommended as treatment for cold AIHA. The need for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in this regimen in those with cold AIHA is unclear at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Plasmapheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasmapheresis can be used as adjunctive treatment to physically remove the IgM antibody from the plasma, leading to a reduction in the rate of hemolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/32\">",
"     32",
"    </a>",
"    ]. This procedure is effective when whole-body exchange techniques are performed, since the antibody, being IgM, is confined to the intravascular space. Plasmapheresis should be performed in as warm an environment as possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/19/12597?source=see_link&amp;anchor=H2#H2\">",
"     \"Indications for therapeutic plasma exchange\", section on 'General therapeutic categories'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of plasmapheresis is relatively short lived as the half-life for replacement of the protein is only five days. It is therefore difficult to use successfully for chronic treatment. There are, however, several indications for plasmapheresis in the treatment of cold agglutinin disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It can be used to reduce severe hemolysis, particularly at initial presentation when the syndrome is due to an infection. In these cases, the thermal amplitude of the agglutinin (ie, the highest temperature at which antibody and antigen are able to interact), may be high, approaching room",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      body temperature, and special precautions may be needed to successfully accomplish the treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It can be used to prepare the patient for surgery. In this setting, plasmapheresis should be performed no more than one to two days prior to the surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In some patients, the symptoms of acrocyanosis are sufficiently severe to require acute relief by plasmapheresis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The neuropathic symptoms of those patients with anti-Pr antibodies and polyneuropathy can be relieved by plasmapheresis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other therapies are less useful. Those interventions that are effective in IgG-mediated warm agglutinin disease are generally of little value in cold agglutinin disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19256?source=see_link\">",
"     \"Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous immunoglobulin (IVIG) may be of benefit for the treatment of the polyclonal cold hemolysis seen with Mycoplasma pneumonia, pending spontaneous clearing of the antibody [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      does not diminish antibody production and any benefit is mediated by downregulation of phagocytosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/39\">",
"       39",
"      </a>",
"      ], which typically requires unacceptably high doses.",
"     </li>",
"     <li>",
"      The spleen is not an organ of destruction in cold agglutinin disease; as a result, splenectomy is generally of no value.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are, however, occasional exceptions to steroid resistance:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with low titer of antibodies of high thermal amplitude (ie, antibodies that produce some hemolysis at 37&ordm;C) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The rare patient with accompanying IgG cold-reacting antibodies. Such patients may respond to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      and splenectomy in a fashion similar to those with IgG warm agglutinins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The patient with concurrent IgG warm agglutinins (eg, induced by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      therapy in a patient with Mycoplasma pneumonia) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recombinant interferon alpha has been used successfully to treat cold agglutinin disease in a small number of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/63/28662?source=see_link\">",
"     Eculizumab",
"    </a>",
"    has shown long-term efficacy in a single patient with hemolysis refractory to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , and intravenous immune globulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33672/abstract/43\">",
"     43",
"    </a>",
"    ]. More experience is needed to determine the role of these modalities.",
"   </p>",
"   <p>",
"    Some patients benefit from modest doses of erythropoietin (4000 units SQ once or twice a week) in order to support an increased rate of RBC production by the bone marrow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/51/12081?source=see_link\">",
"       \"Patient information: Autoimmune hemolytic anemia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cold agglutinin disease may arise secondary to infection (eg, mycoplasma pneumonia, infectious mononucleosis), or may reflect the presence of an underlying lymphoproliferative disorder ranging from benign monoclonal gammopathy to malignant lymphoma. Symptoms are related to the presence of anemia secondary to hemolysis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      to in vivo red blood cell agglutination secondary to exposure to cold (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The diagnosis of cold agglutinin disease is made by demonstrating the presence of significant titers of a cold agglutinin in adequately prepared blood specimens along with a positive Coombs test for bound complement. The cold agglutinin is most often an IgM antibody with specificity for the I or i red blood cell antigen (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Laboratory findings'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Treatment of mildly symptomatic cold agglutinin disease (eg, mild degrees of acrocyanosis or anemia) is mainly supportive, and consists of avoidance of exposure to cold and additional sources of complement (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Special precautions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Avoidance of cold'",
"      </a>",
"      above). When there is evidence for its presence, treatment of an underlying lymphoma is often successful in reducing signs and symptoms of cold agglutinin disease.",
"     </li>",
"     <li>",
"      In the presence of severe signs and symptoms, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      (with attention to the toxicity of the combined regimen). Low-dose alkylating agents (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      ) or interferon may also be used but are usually less effective (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Only highly selected patients are expected to respond to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      splenectomy (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Other agents'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      When signs and symptoms of cold agglutinin disease are severe, especially in the setting of an acute infection or prior to a surgical procedure, we recommend the adjunctive use of plasmapheresis to remove the cold agglutinin (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Special precautions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Plasmapheresis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/1\">",
"      Silberstein LE, Berkman EM, Schreiber AD. Cold hemagglutinin disease associated with IgG cold-reactive antibody. Ann Intern Med 1987; 106:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/2\">",
"      Berentsen S. How I manage cold agglutinin disease. Br J Haematol 2011; 153:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/3\">",
"      Crisp D, Pruzanski W. B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins). Am J Med 1982; 72:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/4\">",
"      Silberstein LE, Litwin S, Carmack CE. Relationship of variable region genes expressed by a human B cell lymphoma secreting pathologic anti-Pr2 erythrocyte autoantibodies. J Exp Med 1989; 169:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/5\">",
"      Williams DM, Clement JR. Malignant histiocytosis appearing as cold-agglutinin disease. South Med J 1985; 78:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/6\">",
"      Richard JL, Vives JF, Bizot M, et al. [Lymphoproliferative syndrome with cold hemagglutinating, cryoprecipitating monoclonal IgM. Anti-Pr1d specificity]. Rev Fr Transfus Immunohematol 1980; 23:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/7\">",
"      Isbister JP, Cooper DA, Blake HM, et al. Lymphoproliferative disease with IgM lambda monoclonal protein and autoimmune hemolytic anemia. A report of four cases and a review of the literature. Am J Med 1978; 64:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/8\">",
"      Michaux L, Dierlamm J, Wlodarska L, et al. Trisomy 3q11-q29 is recurrently observed in B-cell non-Hodgkin's lymphomas associated with cold agglutinin syndrome. Ann Hematol 1998; 76:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/9\">",
"      Michaux L, Dierlamm J, Wlodarska I, et al. Trisomy 3 is a consistent chromosome change in malignant lymphoproliferative disorders preceded by cold agglutinin disease. Br J Haematol 1995; 91:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/10\">",
"      Wortman J, Rosse W, Logue G. Cold agglutinin autoimmune hemolytic anemia in nonhematologic malignancies. Am J Hematol 1979; 6:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/11\">",
"      Feizi T. Monotypic cold agglutinins in infection by mycoplasma pneumoniae. Nature 1967; 215:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/12\">",
"      Horwitz CA, Moulds J, Henle W, et al. Cold agglutinins in infectious mononucleosis and heterophil-antibody-negative mononucleosis-like syndromes. Blood 1977; 50:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/13\">",
"      Terada K, Tanaka H, Mori R, et al. Hemolytic anemia associated with cold agglutinin during chickenpox and a review of the literature. J Pediatr Hematol Oncol 1998; 20:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/14\">",
"      Mickley H, S&oslash;rensen PG. Immune haemolytic anaemia associated with ampicillin dependent warm antibodies and high titre cold agglutinins in a patient with Mycoplasma pneumonia. Scand J Haematol 1984; 32:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/15\">",
"      Bessman JD, Banks D. Spurious macrocytosis, a common clue to erythrocyte cold agglutinins. Am J Clin Pathol 1980; 74:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/16\">",
"      Hinchliffe RF, Bellamy GJ, Lilleyman JS. Use of the Technicon H1 hypochromia flag in detecting spurious macrocytosis induced by excessive K2-EDTA concentration. Clin Lab Haematol 1992; 14:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/17\">",
"      Bedrosian CL, Simel DL. Cold hemagglutinin disease in the operating room. South Med J 1987; 80:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/18\">",
"      Agarwal SK, Ghosh PK, Gupta D. Cardiac surgery and cold-reactive proteins. Ann Thorac Surg 1995; 60:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/19\">",
"      Beebe DS, Bergen L, Palahniuk RJ. Anesthetic management of a patient with severe cold agglutinin hemolytic anemia utilizing forced air warming. Anesth Analg 1993; 76:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/20\">",
"      Talisman R, Lin JT, Soroff HS, Galanakis D. Gangrene of the back, buttocks, fingers, and toes caused by transient cold agglutinemia induced by a cooling blanket in a patient with sepsis. Surgery 1998; 123:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/21\">",
"      Ulvestad E. Paradoxical haemolysis in a patient with cold agglutinin disease. Eur J Haematol 1998; 60:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/22\">",
"      Budmiger H, Rhyner K, Siegenthaler-Zuber G, Bollinger A. [Idiopathic cold agglutinin disease. Clinical aspects, therapy and course in 6 patients]. Schweiz Med Wochenschr 1988; 118:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/23\">",
"      Lee EJ, Kueck B. Rituxan in the treatment of cold agglutinin disease. Blood 1998; 92:3490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/24\">",
"      Bauduer F. Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma. Br J Haematol 2001; 112:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/25\">",
"      Zaja F, Russo D, Fuga G, et al. Rituximab in a case of cold agglutinin disease. Br J Haematol 2001; 115:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/26\">",
"      Engelhardt M, Jakob A, Ruter B, et al. Severe cold hemagglutinin disease (CHD) successfully treated with rituximab. Blood 2002; 100:1922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/27\">",
"      Sch&ouml;llkopf C, Kjeldsen L, Bjerrum OW, et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma 2006; 47:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/28\">",
"      Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica 2006; 91:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/29\">",
"      Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 2004; 103:2925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/30\">",
"      Berentsen S, Randen U, V&aring;gan AM, et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood 2010; 116:3180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/31\">",
"      Barcellini W, Zaja F, Zaninoni A, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood 2012; 119:3691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/32\">",
"      Siami FS, Siami GA. A last resort modality using cryofiltration apheresis for the treatment of cold hemagglutinin disease in a Veterans Administration hospital. Ther Apher Dial 2004; 8:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/33\">",
"      Geurs F, Ritter K, Mast A, Van Maele V. Successful plasmapheresis in corticosteroid-resistant hemolysis in infectious mononucleosis: role of autoantibodies against triosephosphate isomerase. Acta Haematol 1992; 88:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/34\">",
"      Zoppi M, Oppliger R, Althaus U, Nydegger U. Reduction of plasma cold agglutinin titers by means of plasmapheresis to prepare a patient for coronary bypass surgery. Infusionsther Transfusionsmed 1993; 20:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/35\">",
"      Pereira A, Mazzara R, Escoda L, et al. Anti-Sa cold agglutinin of IgA class requiring plasma-exchange therapy as early manifestation of multiple myeloma. Ann Hematol 1993; 66:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/36\">",
"      Valbonesi M, Guzzini F, Zerbi D, et al. Successful plasma exchange for a patient with chronic demyelinating polyneuropathy and cold agglutinin disease due to anti-Pra. J Clin Apher 1986; 3:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/37\">",
"      Gertz MA. Management of cold haemolytic syndrome. Br J Haematol 2007; 138:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/38\">",
"      Gertz MA. Cold hemolytic syndrome. Hematology Am Soc Hematol Educ Program 2006; :19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/39\">",
"      Schreiber AD, Herskovitz BS, Goldwein M. Low-titer cold-hemagglutinin disease. Mechanism of hemolysis and response to corticosteroids. N Engl J Med 1977; 296:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/40\">",
"      Lahav M, Rosenberg I, Wysenbeek AJ. Steroid-responsive idiopathic cold agglutinin disease: a case report. Acta Haematol 1989; 81:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/41\">",
"      Rordorf R, Barth A, Nydegger U, Tobler A. [Treatment of severe idiopathic cold-agglutinin diseases using interferon-alpha 2b]. Schweiz Med Wochenschr 1994; 124:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/42\">",
"      Fest T, de Wazi&egrave;res B, Lamy B, et al. Successful response to alpha-interferon 2b in a refractory IgM autoagglutinin-mediated hemolytic anemia. Ann Hematol 1994; 69:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33672/abstract/43\">",
"      R&ouml;th A, H&uuml;ttmann A, Rother RP, et al. Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood 2009; 113:3885.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7084 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-1.234.2.38-35693F307E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_56_33672=[""].join("\n");
var outline_f32_56_33672=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Changes on exposure to cold",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Other physical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Benign chronic cold agglutinin syndrome and malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antiglobulin (Coombs) test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cold agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SPECIAL PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Avoidance of cold",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cytotoxic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Plasmapheresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7084\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7084|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/55/10101\" title=\"picture 1\">",
"      Livedo reticularis in cold agglutinin disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/10/15527\" title=\"picture 2\">",
"      Cold agglutinin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7084|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/58/26540\" title=\"table 1\">",
"      Types of cold agglutinins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/6/39020\" title=\"table 2\">",
"      Coombs test in AIHA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19256?source=related_link\">",
"      Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/19/12597?source=related_link\">",
"      Indications for therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31018?source=related_link\">",
"      Infectious mononucleosis in adults and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/16/21767?source=related_link\">",
"      Macrocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/5/3162?source=related_link\">",
"      Mycoplasma pneumoniae infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22522?source=related_link\">",
"      Overview of cryoglobulins and cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/2/16422?source=related_link\">",
"      Paroxysmal cold hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30535?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/2/20521?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/51/12081?source=related_link\">",
"      Patient information: Autoimmune hemolytic anemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42214?source=related_link\">",
"      Transfusion reactions caused by chemical and physical agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/62/14313?source=related_link\">",
"      Treatment of autoimmune hemolytic anemia: Warm agglutinins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_56_33673="Adrenoleukodystrophy";
var content_f32_56_33673=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adrenoleukodystrophy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/56/33673/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/56/33673/contributors\">",
"     Alan K Percy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/56/33673/contributors\">",
"     Ronald JA Wanders, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/56/33673/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/56/33673/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/56/33673/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/56/33673/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/56/33673/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/56/33673/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenoleukodystrophy (ALD; MIM #300100) is a peroxisomal disorder of beta-oxidation that results in accumulation of very long chain fatty acids (VLCFA) in all tissues. ALD consists of a spectrum of phenotypes (including adrenomyeloneuropathy, AMN) that vary in the age and severity of clinical presentation (",
"    <a class=\"graphic graphic_table graphicRef70311 graphicRef80404 graphicRef59029 \" href=\"mobipreview.htm?41/61/42974\">",
"     table 1A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These conditions are known as the",
"    <span class=\"nowrap\">",
"     ALD/AMN",
"    </span>",
"    complex. There is evidence that variations in methionine metabolism may contribute to the phenotypic variability noted in this",
"    <span class=\"nowrap\">",
"     ALD/AMN",
"    </span>",
"    complex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathophysiology, clinical manifestations, and treatment of ALD will be reviewed here. Other peroxisomal disorders, including neonatal adrenoleukodystrophy, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8570?source=see_link\">",
"     \"Peroxisomal disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;ALD is the most common peroxisomal disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/5\">",
"     5",
"    </a>",
"    ]. In a report that included data from the two laboratories that perform most of the assays for the disorder, the minimum frequency in the United States was estimated at 1 in 21,000 and 1 in 16,800 for hemizygotes and hemizygotes plus heterozygotes, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ALD is an X-linked disorder. It is caused by mutations in the ATP-Binding Cassette, Subfamily D, Member 1 gene (ABCD1 gene), located at Xq28, that encodes an ATP-binding cassette (ABC) transporter, similar to cystic fibrosis transmembrane conductance regulator (CFTR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. The ABC transporter helps form the channel through which VLCFAs move into the peroxisome, probably as CoA-esters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/12\">",
"     12",
"    </a>",
"    ]. The phenotype does not correlate with the type of mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ABCD1 mutations may prevent normal transport of very long chain fatty acids (VLCFA) into peroxisomes, thereby preventing beta-oxidation and breakdown of VLCFA. Accumulation of abnormal VLCFA in affected organs (central nervous system, Leydig cells of the testes, and the adrenal cortex) is presumed to underlie the pathologic process of the adrenoleukodystrophies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distribution of the adrenoleukodystrophy protein (ALDP) maps to regions of high metabolic activity (heart, skeletal muscle, and liver) and to critical neural regions, including subcortical and cerebellar white matter, hypothalamus, ACTH-producing cells in pituitary, and dorsal root ganglia (DRG). Of interest, the DRG undergo atrophy in AMN. Remarkably, ALDP is scarcely present in corticospinal tract and corpus callosum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathology in the central nervous system (CNS) is characterized by diverse immune responses involving cellular and humoral mechanisms as well as cytokines and complement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/15\">",
"     15",
"    </a>",
"    ]. A case series of three males with X-linked adrenoleukodystrophy and two with X-linked adrenomyeloneuropathy cites head trauma as the initiating feature in the cerebral neuropathology and a possible mechanism for the associated immune response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/16\">",
"     16",
"    </a>",
"    ]. The profound mononuclear response appears to be the result of abnormal signaling to receptors on microglia leading to microglial apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, evidence of oxidative stress and damage (lipid peroxidation) is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. However, mitochondrial dysfunction was not noted in muscle or brain from individuals with ALD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/20\">",
"     20",
"    </a>",
"    ]. Alternatively, it is possible that VLCFA toxicity leads to mitochondrial dysfunction and abnormal calcium regulation, as suggested by in vitro studies in neurons and glia from rat brain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the adrenal gland, abnormal VLCFA may directly alter cellular function by inhibiting the effects of ACTH on the adrenocortical cells, or indirectly by initiating an autoimmune response. In almost all instances, adrenocortical failure occurs along with irreversible degenerative neurologic defects. Adrenal failure may predate, occur simultaneously with, or follow the onset of the neurologic deterioration.",
"   </p>",
"   <p>",
"    Comparison of this pathophysiology to that of other peroxisomal disorders is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8570?source=see_link\">",
"     \"Peroxisomal disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NEUROPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the central nervous system, ALD is characterized by inflammatory demyelination, resulting in confluent and bilaterally symmetric loss of myelin in the cerebral and cerebellar white matter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The parieto-occipital regions are usually affected first, with asymmetric progression of the lesions toward the frontal or temporal lobes. In general, arcuate fibers are spared, except in chronic cases. Axonal loss may be considerable, but myelin loss is usually greater. Lesions may sometimes involve the brainstem, especially the pons. The spinal cord is usually spared, except for bilateral corticospinal tract degeneration.",
"   </p>",
"   <p>",
"    When peripheral nerves are affected in ALD, characteristic lamellar and lamellar-lipid inclusions are seen in Schwann cell cytoplasm or within endoneurial macrophages. CNS macrophages, but not oligodendrocytes, may also have inclusions. Spicular or trilaminar inclusions may also occur in the CNS.",
"   </p>",
"   <p>",
"    The inflammatory demyelination in ALD appears to occur in the following specific sequence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Enlargement of the extraneural space",
"     </li>",
"     <li>",
"      Vacuolization and myelin swelling with reactive astrocytes and macrophage infiltration",
"     </li>",
"     <li>",
"      Perivascular lymphocytic and increased permeability of the blood brain barrier",
"     </li>",
"     <li>",
"      Loss of myelin with lipophage formation",
"     </li>",
"     <li>",
"      Loss of oligodendroglia and axons",
"     </li>",
"     <li>",
"      Dystrophic mineralization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lymphocytes in acute demyelinative lesions of patients with childhood cerebral X-ALD are mainly CD8 cytotoxic T cells. There is cytolysis of oligodendrocytes. In addition, CD1 molecules have been noted, suggesting that CD1-mediated lipid antigen presentation may occur with VLCFA-containing lipids, such as gangliosides or proteolipids, acting as antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/25\">",
"     25",
"    </a>",
"    ]. In vitro studies suggest that the VLCFA accumulation that occurs in the absence of ABDC1 function promotes inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In AMN, both inflammatory and noninflammatory demyelination lesions occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/22\">",
"     22",
"    </a>",
"    ]. Affected individuals also develop a degenerative axonopathy that involves the ascending and descending tracts of the spinal cord, especially in fasciculus gracilis and the lateral corticospinal tracts. The histologic pattern is Wallerian degeneration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/27\">",
"     27",
"    </a>",
"    ]. Mitochondrial pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/28\">",
"     28",
"    </a>",
"    ] and oxidative stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/18\">",
"     18",
"    </a>",
"    ] also contribute to pathogenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities primarily affect the central nervous system, adrenal cortex, and Leydig cells in the testes. Affected males have one of three main phenotypes and can present from childhood through adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/29\">",
"     29",
"    </a>",
"    ]. Neurologic signs that resemble AMN develop in up to 50 percent of carrier females [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/30\">",
"     30",
"    </a>",
"    ]. The clinical course in females is milder, and the onset is later (after age 35 years) than in affected males.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Childhood cerebral forms",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef70311 \" href=\"mobipreview.htm?23/53/24413\">",
"     table 1A",
"    </a>",
"    ) ALD presents between four and eight years of age (peak seven years), representing approximately 35 percent of all phenotypes in the",
"    <span class=\"nowrap\">",
"     ALD/AMN",
"    </span>",
"    complex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/30\">",
"     30",
"    </a>",
"    ]. It is rare after 15 years of age and almost never occurs before age three.",
"   </p>",
"   <p>",
"    Boys typically present with learning disabilities and behavior problems that are often diagnosed as attention deficit hyperactivity disorder, and may respond to stimulant medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/1\">",
"     1",
"    </a>",
"    ]. This is followed by neurologic deterioration that includes increasing cognitive and behavioral abnormalities, blindness, and the development of quadriparesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/31\">",
"     31",
"    </a>",
"    ]. In contrast, one report describes preservation of significant visual function in an individual with ALD, despite advanced CNS involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/32\">",
"     32",
"    </a>",
"    ]. Approximately 20 percent of affected boys have seizures, which may be the first manifestation in some. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=see_link&amp;anchor=H830607547#H830607547\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32665?source=see_link&amp;anchor=H6#H6\">",
"     \"Specific learning disabilities in children: Clinical features\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most affected individuals have adrenal insufficiency. Some have hyperpigmented skin due to increased ACTH secretion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23369?source=see_link\">",
"     \"Causes and clinical manifestations of primary adrenal insufficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Deterioration progresses at a variable rate. Rapid progression is common, with total disability in six months to two years, and death within 5 to 10 years of diagnosis.",
"   </p>",
"   <p>",
"    The differential diagnosis of individuals presenting with these symptoms and cerebral involvement includes acute demyelinating encephalomyelitis, and other leukodystrophies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/32/12809?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/60/4038?source=see_link\">",
"     \"Krabbe disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/27/42421?source=see_link\">",
"     \"Metachromatic leukodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Adrenomyeloneuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;AMN typically presents in adult males between 20 and 40 years of age (average 28 years) and comprises approximately 40 to 45 percent of",
"    <span class=\"nowrap\">",
"     ALD/AMN",
"    </span>",
"    complex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The primary manifestation is spinal cord dysfunction with progressive stiffness and weakness of the legs (spastic paraparesis), abnormal sphincter control, and sexual dysfunction. Gonadal dysfunction may precede motor abnormalities. The majority have adrenal insufficiency. AMN may also present as a progressive cerebellar disorder (",
"    <a class=\"graphic graphic_table graphicRef80404 \" href=\"mobipreview.htm?42/40/43660\">",
"     table 1B",
"    </a>",
"    ). Physiologic and radiologic (MR fractional anisotropy) assessments confirmed the presence of sensorimotor abnormalities in the dorsal columns extending into brainstem, and correlated with overall severity in AMN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/33\">",
"     33",
"    </a>",
"    ]. Auditory brainstem evoked responses correlated more with AMN than ALD, while auditory function was generally normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23369?source=see_link\">",
"     \"Causes and clinical manifestations of primary adrenal insufficiency in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/46/44777?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cerebral abnormalities affect up to 45 percent of those with AMN. Their illness progresses more rapidly. Rapid neurologic progression with serious cognitive and behavioral disturbances occurs in 10 to 20 percent and may lead to total disability and early death.",
"   </p>",
"   <p>",
"    The differential diagnosis of individuals presenting with these symptoms includes multiple sclerosis, amyotrophic lateral sclerosis, vitamin B12 deficiency, and progressive spastic paraparesis, including hereditary spastic paraparesis (HSP). These disorders are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/32/12809?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=see_link\">",
"     \"Diagnosis of multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32426?source=see_link\">",
"     \"Disorders affecting the spinal cord\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Addison disease only",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal insufficiency is the only sign of ALD in approximately 10 percent of affected individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. This form presents in males between two years of age and adulthood, but usually before 7.5 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/30\">",
"     30",
"    </a>",
"    ]. ALD is the cause for up to 20 percent of boys with idiopathic Addison disease.",
"   </p>",
"   <p>",
"    Signs include unexplained vomiting, weakness, or coma. Some individuals have hyperpigmented skin due to increased ACTH secretion. Biochemical evidence of adrenal insufficiency can be present for up to two years before the development of clinical signs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/38\">",
"     38",
"    </a>",
"    ]. Some males with ABCD gene mutations are reported to have biochemical evidence but no clinical features of adrenal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12408?source=see_link&amp;anchor=H2#H2\">",
"     \"Unusual causes of adrenal insufficiency\", section on 'Adrenoleukodystrophy and adrenomyeloneuropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most individuals who present with isolated adrenal insufficiency develop AMN by middle age. In boys presenting with Addison disease, prompt evaluation for ALD is important because early diagnosis is likely to improve outcomes from hematopoietic stem cell transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23369?source=see_link\">",
"     \"Causes and clinical manifestations of primary adrenal insufficiency in children\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H18\">",
"     'Hematopoietic cell transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other presentations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical presentations occur in approximately 5 to 10 percent of affected males. These include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Onset between 4 and 10 years of age or, less commonly, in adolescents or adults of increased intracranial pressure with headache and signs of localized brain disease (eg, hemiparesis, visual field defect, or aphasia)",
"     </li>",
"     <li>",
"      Onset in an adult of progressive paralysis, dementia, and behavior disturbance",
"     </li>",
"     <li>",
"      Presentation in a child or adult with progressive incoordination and ataxia",
"     </li>",
"     <li>",
"      Impotence without other findings in a man with a family history of ALD",
"     </li>",
"     <li>",
"      Asymptomatic",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Female carriers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Female carriers may be symptomatic depending upon the pattern of X-chromosome inactivation (also known as lyonization) (",
"    <a class=\"graphic graphic_table graphicRef59029 \" href=\"mobipreview.htm?18/19/18748\">",
"     table 1C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/40\">",
"     40",
"    </a>",
"    ]. Affected individuals typically present with mild spastic paraparesis in mid-adulthood (average age of 43 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/31\">",
"     31",
"    </a>",
"    ]. An AMN-like syndrome affects up to 50 percent of female heterozygotes in middle age or later, although cerebral disturbance is uncommon. Adrenal insufficiency is rare in females.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of ALD may be raised by the above clinical signs or symptoms, including isolated adrenal insufficiency. Other individuals come to attention because of a family history of ALD. The diagnostic approach is the same for both groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In males, the VLCFA panel is highly sensitive for detecting",
"      <span class=\"nowrap\">",
"       ALD/AMN,",
"      </span>",
"      and is the appropriate first step in the diagnosis. If the VLCFA levels are elevated, or if the ratios of VLCFA are abnormal, a mutation analysis should be performed to confirm the diagnosis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Laboratory testing'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In females, the VLCFA panel is less sensitive for detecting ALD (15 percent of carriers will have normal results). Therefore, the definitive test for suspected female carriers is a mutation analysis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Laboratory testing'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All individuals with confirmed",
"    <span class=\"nowrap\">",
"     ALD/AMN",
"    </span>",
"    complex, including symptomatic female heterozygotes, should undergo neuroimaging to determine if cerebral involvement is present (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Neuroimaging'",
"    </a>",
"    below), and testing of adrenal function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/46/44777?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17255?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma concentration of VLCFA is elevated in nearly all males with the disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/41\">",
"     41",
"    </a>",
"    ]. VLCFA concentration is increased in plasma or fibroblasts in approximately 85 percent of female carriers. Testing typically includes three VLCFA parameters: the level of hexacosanoic acid (C26:0), and the ratio of hexacosanoic acid to tetracosanoic acid",
"    <span class=\"nowrap\">",
"     (C26:0/C24:0),",
"    </span>",
"    and to docosanoic acid",
"    <span class=\"nowrap\">",
"     (C26:0/C22:0)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/41\">",
"     41",
"    </a>",
"    ]. Alternatively, VLCFA levels may be determined in blood leukocytes using gas chromatography-mass spectrometry (CC-MS). Combining this test with measurement of plasma VLCFA improves sensitivity for identifying heterozygotes; in one study 92 percent of heterozygotes were identified by combined plasma and leukocyte analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/42\">",
"     42",
"    </a>",
"    ]. VLCFA levels are also elevated in some other peroxisomal disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8570?source=see_link\">",
"     \"Peroxisomal disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most males, the combination of typical clinical features and markedly elevated VLCFA levels is sufficient to establish the diagnosis of X-ALD. For optimal certainty of the diagnosis and to facilitate genetic counseling, the diagnosis should be confirmed by molecular genetic testing of the ABCD1 gene locus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/43\">",
"     43",
"    </a>",
"    ]. Molecular genetic testing is particularly important in cases with borderline VLCFA levels, atypical features, or in females. A description of the technique and list of accepted laboratories providing these tests is available at",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     www.genetests.org",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Adrenal function should be evaluated by measurement of plasma ACTH concentration and the rise in plasma cortisol concentration following ACTH stimulation. Testing is abnormal in 90 percent of boys with neurologic signs, and in 70 percent of men with AMN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/30\">",
"     30",
"    </a>",
"    ]. ACTH levels are often increased already during the first year of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/38\">",
"     38",
"    </a>",
"    ]. Females usually have normal adrenal function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/46/44777?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17255?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cranial MRI is often normal in those with AMN, it is always abnormal in symptomatic males with other forms of ALD, demonstrating demyelination in cerebral white matter. The abnormality can range from mild to severe. Lesions are usually bilateral, but are limited to only one side in rare instances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/44\">",
"     44",
"    </a>",
"    ]. The occipitoparietal region is typically affected (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61967 \" href=\"mobipreview.htm?41/32/42498\">",
"     image 1",
"    </a>",
"    ). However, the frontal lobe is involved up to 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The progression of the disease correlates with the presence of contrast enhancement on T1-weighted MR images [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proton MR spectroscopy detects white matter abnormalities that may not be apparent on conventional MR imaging and may predict disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. In one report, this technique was evaluated in 25 individuals with X-linked ALD, ages 2 to 43 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/49\">",
"     49",
"    </a>",
"    ]. MRI and proton MR spectroscopy were performed at baseline, and follow-up MRI was performed at an average of 3.5 years. Based on the MRI findings, participants were classified as noncerebral, cerebral nonprogressive, or cerebral progressive. A concentration ratio of N-acetylaspartate to choline of &ge;5.0 predicted disease progression with a sensitivity and specificity of 100 and 83 percent, respectively, and a positive and negative predictive value of 66 and 100 percent, respectively.",
"   </p>",
"   <p>",
"    Although the conventional brain MRI is normal in individuals with AMN, axonal changes may be seen on brain magnetic resonance spectroscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/50\">",
"     50",
"    </a>",
"    ] and diffusion tensor based imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/51\">",
"     51",
"    </a>",
"    ]. Magnetization transfer MRI may be effective in determining the extent of spinal cord involvement in AMN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/52\">",
"     52",
"    </a>",
"    ]. Functional MRI (fMRI) and proton MR spectroscopy may reveal prominent changes in brain not apparent on conventional cranial MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/53\">",
"     53",
"    </a>",
"    ]. High field strength MR-spectroscopy can distinguish adult-onset X-ALD from AMN, but does not distinguish AMN from female heterozygotes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Visual evoked responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;For asymptomatic males without radiologic abnormalities, serial measurement of visual evoked responses (VER) can be used to monitor disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management is directed at treating adrenal insufficiency if present. Dietary therapy to reduce levels of VLCFA has not been effective except possibly in very early stages of the disease (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Dietary therapy'",
"    </a>",
"    below). Pharmacologic agents are under investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/56\">",
"     56",
"    </a>",
"    ]. Hematopoietic stem cell transplantation may be an option in some cases. Treatment options may be targeted to specific phenotypes, including asymptomatic individuals (",
"    <a class=\"graphic graphic_table graphicRef70311 graphicRef80404 graphicRef59029 \" href=\"mobipreview.htm?41/61/42974\">",
"     table 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Adrenal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticosteroid replacement therapy is essential in those with adrenal insufficiency. However, it has no effect on neurologic abnormalities in adrenoleukodystrophy (ALD). Adrenal function should be evaluated yearly in affected males without adrenal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/46/44777?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17255?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31078?source=see_link\">",
"     \"Treatment of adrenal insufficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic cell transplantation (HCT), is emerging as the treatment of choice for individuals with early stages of cerebral involvement in ALD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Stem cells can be harvested from a variety of hematologic sources, including peripheral blood, bone marrow, and umbilical cord blood. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most appropriate candidates for HCT are boys with neurologic abnormalities and evidence of CNS involvement on MRI who are early in their disease course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/30\">",
"     30",
"    </a>",
"    ]. We do not recommend HCT for boys without MRI evidence of cerebral involvement, because approximately half of this group will remain free of neurological disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/57\">",
"     57",
"    </a>",
"    ]. Conversely, there is little evidence that HCT improves clinical outcomes in individuals with advanced neurologic disease, so HCT is not recommended for this group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/57\">",
"     57",
"    </a>",
"    ]. HCT does not appear to affect the course of adrenal dysfunction in patients with ALD, so patients require ongoing monitoring for adrenal dysfunction, and treatment, if necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term outcomes of HCT were illustrated in a case series in which 12 boys with childhood cerebral ALD were followed for 5 to 10 years after bone marrow transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/61\">",
"     61",
"    </a>",
"    ]. MRI abnormalities reversed in two, improved in one, and did not change in one. Eight participants stabilized and remained unchanged following an initial period of continued demyelination. Motor function stayed normal or improved in 10, verbal intelligence stayed within a normal range for 11, performance abilities improved or remained stable in 7, and stabilized following a decline in 5. The plasma VLFA concentration decreased by 55 percent and remained slightly above the normal range.",
"   </p>",
"   <p>",
"    Another study evaluated the outcome of HCT of 126 boys with cerebral ALD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/62\">",
"     62",
"    </a>",
"    ]. Results were found to be highly favorable in a 25-member subgroup in which transplant was performed in the early stage of the illness (92 percent five-year survival). A later retrospective report identified a nontransplanted 30-member subgroup of patients with early-stage cerebral ALD who were matched by neurologic disability and MRI severity scores with a transplanted 19-member subgroup with early-stage cerebral ALD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/63\">",
"     63",
"    </a>",
"    ]. Early-stage disease was defined as having no or one neurological deficit (this scale does not include cognitive or behavioral symptoms), and mild abnormalities on brain MRI (MRI severity score &lt;9 on a 34 point scale) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/62\">",
"     62",
"    </a>",
"    ]. For those with these baseline characteristics, the five-year survival was significantly worse for the nontransplanted patients compared with the transplanted group (54 versus 95 percent).",
"   </p>",
"   <p>",
"    Further insight into the effect of disease stage on HCT outcomes was provided by a study of 60 boys undergoing HCT at a single center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/64\">",
"     64",
"    </a>",
"    ]. All subjects had MRI evidence of active cerebral disease at HCT, but half had more severe radiographic findings (defined as a Loes severity score &gt;10), and 40 percent had clinical evidence of disease. Predicted survival five years after HCT was significantly lower among subjects with more severe radiographic findings (60 percent), as compared with those with mild radiographic findings (89 percent). Predicted five-year survival among boys with clinical evidence of neurologic dysfunction was also low (66 percent), as compared with asymptomatic boys (91 percent), but this difference was not statistically significant. &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Because of the apparent benefits of HCT to individuals with early cerebral involvement in ALD, some experts also recommend HCT for those with AMN and mild cerebral involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/57\">",
"     57",
"    </a>",
"    ]. However, this practice has not been studied in clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Dietary therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restriction of dietary VLCFA can be accomplished by reducing the intake of fatty foods. However, this approach will not decrease VLCFA concentration because endogenous synthesis continues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dietary treatment has been attempted with Lorenzo's oil, a mixture of glyceroltrioleate and glyceroltrierucate. Lorenzo's oil reduces the synthesis of VLCFA by competitive inhibition of the enzyme responsible for elongation of saturated fatty acids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/65\">",
"     65",
"    </a>",
"    ]. However, the results of clinical studies are conflicting. In two studies, administration of Lorenzo's oil to individuals with AMN normalized plasma concentration of VLCFA but did not stop disease progression in those with neurologic abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Adverse effects included thrombocytopenia and elevated liver enzymes.",
"   </p>",
"   <p>",
"    A subsequent open label study identified 89 asymptomatic boys (mean age 4.8 years at study entry) with ALD identified by screening for VLCFA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/68\">",
"     68",
"    </a>",
"    ]. All 89 were treated with Lorenzo's oil, 2 to 3",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per day, and moderate fat restriction. At a mean follow up of 6.9 years, 66 children (74 percent) were normal by neurologic examination and brain MRI, 21 (24 percent) had MRI abnormalities, and 10 (11 percent) had neurologic abnormalities consistent with the childhood cerebral form. This development of neurologic involvement appears to be less than in historical controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/69\">",
"     69",
"    </a>",
"    ]. Limitations of this study include its open label design, lack of concurrent controls, and relatively short follow-up. In addition, 14 participants had undergone HCT therapy, after which data were censored, and 12 (14 percent) were lost to follow-up. Lorenzo's oil did not relieve oxidative stress or peroxidation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of beginning treatment with Lorenzo's oil in even earlier stages of ALD is currently being studied in an open-label trial. A preliminary report described the course of 37 boys treated with Lorenzo's oil for a mean of 1.7 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/65\">",
"     65",
"    </a>",
"    ]. The subjects were typically younger than those enrolled in the study of 89 boys described above (mean age 3.56 years at study entry), and all were asymptomatic at the beginning of treatment. Thirty-four boys have remained normal in all respects, while three have developed mild MRI abnormalities.",
"   </p>",
"   <p>",
"    Little information is available about the effects of Lorenzo's oil on the clinical course of AMN. In an open-label study of Lorenzo's oil in 45 adults with AMN but no cerebral involvement, the treated group appeared to have slower progression of disease as compared to the estimated disease progress in untreated individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/65\">",
"     65",
"    </a>",
"    ]. This study prompted the initiation of a placebo-controlled trial of Lorenzo's oil in AMN, for which results are not yet available.",
"   </p>",
"   <p>",
"    This limited observational evidence suggests that Lorenzo's oil may delay the progression of disease in individuals with early or mild ALD and perhaps also for AMN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/1,65\">",
"     1,65",
"    </a>",
"    ]. Therefore, we suggest that treatment with Lorenzo's oil be offered to individuals with presymptomatic ALD (ie, those with laboratory studies diagnostic of ALD, but without abnormal neurologic or MRI findings). However, the efficacy of Lorenzo's oil is probably substantially less than that of HCT. We recommend careful monitoring of patients treated with Lorenzo's oil, and HCT should be considered if any symptoms or signs of neurologic disease develop. We also suggest treatment with Lorenzo's oil for individuals with Addison disease only and normal MRI, as many individuals with this phenotype will become symptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/47/42743?source=see_link\">",
"     Lovastatin",
"    </a>",
"    and sodium phenylacetate reduce VLCFA concentration in ALD fibroblasts, and may be possible therapeutic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a preliminary report,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/47/42743?source=see_link\">",
"     lovastatin",
"    </a>",
"    reduced plasma VLCFA levels in 12 affected individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/72\">",
"     72",
"    </a>",
"    ]. However, a small randomized trial suggested that the decrease in plasma levels of VLCFA is small and transient, and is probably a nonspecific result of a concurrent decrease in plasma LDL cholesterol; the treatment did not reduce VLCFA levels in peripheral blood lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/73\">",
"     73",
"    </a>",
"    ]. Thus, the justification for larger clinical trials of lovastatin is questionable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Phenylbutyrate upregulates the ALD-related gene to generate more ALD-related protein, providing a molecular-biochemical basis for its potential efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. Alternatively, upregulation of the alternative fatty acid oxidation pathway (omega-oxidation, which initiates fatty oxidation degradation from the methyl end of the fatty acid rather than the carboxyl end as in typical beta-oxidation) could be a potential avenue for promoting VLCFA metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/77\">",
"     77",
"    </a>",
"    ]. Neither strategy is currently recommended outside of clinical trials.",
"   </p>",
"   <p>",
"    Two additional reports describe alternative strategies that might lead to new treatment approaches in the future. In one, a flavenoid derivative reduced VLCFA levels in cultured fibroblasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/78\">",
"     78",
"    </a>",
"    ]. In the second, delivery of insulin growth factor 1 (IGF-1) or neurotrophin 3 (NT-3) genes into the cerebrospinal fluid provided protection against demyelination in a mouse model of X-ALD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A preliminary study suggests that hematopoietic stem cell gene therapy with a lentiviral vector can provide clinical benefits in ALD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/56/33673/abstract/80\">",
"     80",
"    </a>",
"    ]. This therapy was given to two ALD patients who were not candidates for allogeneic HCT because matched donors were not available. Autologous CD34+ from these patients were genetically corrected ex vivo with a lentiviral vector encoding wild-type ABCD1, and then re-infused into the patients after they had received myeloablative treatment.",
"   </p>",
"   <p>",
"    Over a span of 24 to 30 months of follow-up, polyclonal reconstitution was detected with 9 to 14 percent of granulocytes, monocytes, and T and B lymphocytes expressing the ALD protein, suggesting that hematopoietic stem cells were transduced in the patients. Moreover, beginning 14 to 16 months after infusion of the genetically corrected cells, the cerebral demyelination in the two patients ceased to progress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adrenoleukodystrophy (ALD) is a peroxisomal disorder of beta-oxidation that results in accumulation of very long chain fatty acids (VLCFA) in all tissues. ALD consists of a spectrum of phenotypes, including childhood cerebral forms, adrenomyeloneuropathy, and Addison disease only. These disorders vary in the age and severity of clinical presentation (",
"      <a class=\"graphic graphic_table graphicRef70311 graphicRef80404 graphicRef59029 \" href=\"mobipreview.htm?41/61/42974\">",
"       table 1A-C",
"      </a>",
"      ). Together, these conditions are known as the",
"      <span class=\"nowrap\">",
"       ALD/AMN",
"      </span>",
"      complex. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ALD is an X-linked disorder, caused by mutations in the ATP-Binding Cassette, Subfamily D, Member 1 gene (ABCD1 gene). The mutations prevent normal transport of very long chain fatty acids (VLCFA) into peroxisomes, thereby preventing beta-oxidation and breakdown of VLCFA. Accumulation of abnormal VLCFA in affected organs (central nervous system, Leydig cells of the testes, and the adrenal cortex) causes the dysfunction seen in these disorders. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Childhood cerebral forms of ALD present between four and eight years of age. Boys typically present with learning disabilities and behavior problems, followed by neurologic deterioration that includes increasing cognitive and behavioral abnormalities, blindness, and the development of quadriparesis. Approximately 20 percent of affected individuals have seizures. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Childhood cerebral forms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adrenomyeloneuropathy typically presents in adult males between 20 and 40 years of age. The primary manifestation is spinal cord dysfunction with progressive stiffness and weakness of the legs (spastic paraparesis), abnormal sphincter control, and sexual dysfunction, and most individuals have adrenal insufficiency. AMN may also present as a progressive cerebellar disorder. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Adrenomyeloneuropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Addison disease only phenotype of ALD presents as isolated adrenal insufficiency, and occurs in approximately 10 percent of individuals with ALD. This form presents in males between two years of age and adulthood, but usually before 7.5 years. Most of these individuals go on to develop AMN by mid adulthood. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Addison disease only'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 50 percent of female carriers of ALD develop an AMN-like syndrome, with mild spastic paraparesis presenting in mid adulthood or later. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Female carriers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The plasma concentration of VLCFA is elevated in nearly all males with the",
"      <span class=\"nowrap\">",
"       ALD/AMN",
"      </span>",
"      complex. The diagnosis should be confirmed by mutation analysis of the ABCD1 gene. All individuals with suspected or confirmed ALD or AMN should be evaluated for adrenal insufficiency, and re-evaluated periodically. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All individuals with adrenal insufficiency, with or without other manifestations of ALD or AMN, should be treated with corticosteroid replacement therapy. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Adrenal insufficiency'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31078?source=see_link\">",
"       \"Treatment of adrenal insufficiency in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend that individuals with cerebral ALD and few or no neurological symptoms be treated with hematopoietic cell transplantation (HCT) rather than no treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ), and rather than dietary therapy (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). This recommendation assumes a definitive diagnosis of cerebral ALD, based on genetic mutation analysis and characteristic abnormal findings on brain MRI. HCT can also be considered for individuals with cerebral AMN, but outcomes for this group of patients have not been studied. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Hematopoietic cell transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that individuals with ALD but without clinical or MRI evidence of cerebral involvement be treated with Lorenzo's oil rather than no treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These individuals are considered to have presymptomatic ALD, based on elevations of VLCFA levels and abnormal results of the genetic mutation analysis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a family history of ALD. This suggestion is based on limited observational evidence suggesting that Lorenzo's oil may delay the progression of disease in individuals with mild disease. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Dietary therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We also suggest treatment with Lorenzo's oil for individuals with AMN or Addison's disease only phenotypes (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). By definition, these individuals have no evidence of inflammatory brain involvement. This suggestion is based primarily on the effects of Lorenzo's oil on the secondary outcome of VLCFA levels; currently minimal information is available about effects on disease progression. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Dietary therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/47/42743?source=see_link\">",
"       lovastatin",
"      </a>",
"      may lower VLCFA in individuals with",
"      <span class=\"nowrap\">",
"       ALD/AMD",
"      </span>",
"      complex. However, the clinical evidence is currently insufficient to support a recommendation for this treatment outside of the context of a well-designed clinical trial. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/1\">",
"      Moser HW, Raymond GV, Dubey P. Adrenoleukodystrophy: new approaches to a neurodegenerative disease. JAMA 2005; 294:3131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/2\">",
"      Berger J, G&auml;rtner J. X-linked adrenoleukodystrophy: clinical, biochemical and pathogenetic aspects. Biochim Biophys Acta 2006; 1763:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/3\">",
"      Linnebank M, Kemp S, Wanders RJ, et al. Methionine metabolism and phenotypic variability in X-linked adrenoleukodystrophy. Neurology 2006; 66:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/4\">",
"      Semmler A, Bao X, Cao G, et al. Genetic variants of methionine metabolism and X-ALD phenotype generation: results of a new study sample. J Neurol 2009; 256:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/5\">",
"      Moser HW, Moser AB. Peroxisomal disorders: overview. Ann N Y Acad Sci 1996; 804:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/6\">",
"      Bezman L, Moser AB, Raymond GV, et al. Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol 2001; 49:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/7\">",
"      Mosser J, Douar AM, Sarde CO, et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 1993; 361:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/8\">",
"      Mosser J, Lutz Y, Stoeckel ME, et al. The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein. Hum Mol Genet 1994; 3:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/9\">",
"      Migeon BR, Moser HW, Moser AB, et al. Adrenoleukodystrophy: evidence for X linkage, inactivation, and selection favoring the mutant allele in heterozygous cells. Proc Natl Acad Sci U S A 1981; 78:5066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/10\">",
"      Holzinger A, Kammerer S, Berger J, Roscher AA. cDNA cloning and mRNA expression of the human adrenoleukodystrophy related protein (ALDRP), a peroxisomal ABC transporter. Biochem Biophys Res Commun 1997; 239:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/11\">",
"      McGuinness MC, Lu JF, Zhang HP, et al. Role of ALDP (ABCD1) and mitochondria in X-linked adrenoleukodystrophy. Mol Cell Biol 2003; 23:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/12\">",
"      van Roermund CW, Visser WF, Ijlst L, et al. The human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl-CoA esters. FASEB J 2008; 22:4201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/13\">",
"      Kemp S, Wanders R. Biochemical aspects of X-linked adrenoleukodystrophy. Brain Pathol 2010; 20:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/14\">",
"      H&ouml;ftberger R, Kunze M, Weinhofer I, et al. Distribution and cellular localization of adrenoleukodystrophy protein in human tissues: implications for X-linked adrenoleukodystrophy. Neurobiol Dis 2007; 28:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/15\">",
"      Hudspeth MP, Raymond GV. Immunopathogenesis of adrenoleukodystrophy: current understanding. J Neuroimmunol 2007; 182:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/16\">",
"      Raymond GV, Seidman R, Monteith TS, et al. Head trauma can initiate the onset of adreno-leukodystrophy. J Neurol Sci 2010; 290:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/17\">",
"      Eichler FS, Ren JQ, Cossoy M, et al. Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy? Ann Neurol 2008; 63:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/18\">",
"      Powers JM, Pei Z, Heinzer AK, et al. Adreno-leukodystrophy: oxidative stress of mice and men. J Neuropathol Exp Neurol 2005; 64:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/19\">",
"      L&oacute;pez-Erauskin J, Galino J, Bianchi P, et al. Oxidative stress modulates mitochondrial failure and cyclophilin D function in X-linked adrenoleukodystrophy. Brain 2012; 135:3584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/20\">",
"      Oezen I, Rossmanith W, Forss-Petter S, et al. Accumulation of very long-chain fatty acids does not affect mitochondrial function in adrenoleukodystrophy protein deficiency. Hum Mol Genet 2005; 14:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/21\">",
"      Hein S, Sch&ouml;nfeld P, Kahlert S, Reiser G. Toxic effects of X-linked adrenoleukodystrophy-associated, very long chain fatty acids on glial cells and neurons from rat hippocampus in culture. Hum Mol Genet 2008; 17:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/22\">",
"      Powers JM. Adreno-leukodystrophy (adreno-testiculo-leukomyelo-neuropathic-complex). Clin Neuropathol 1985; 4:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/23\">",
"      Ferrer I, Aubourg P, Pujol A. General aspects and neuropathology of X-linked adrenoleukodystrophy. Brain Pathol 2010; 20:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/24\">",
"      Powers JM, Liu Y, Moser AB, Moser HW. The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol 1992; 51:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/25\">",
"      Ito M, Blumberg BM, Mock DJ, et al. Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy: morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation. J Neuropathol Exp Neurol 2001; 60:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/26\">",
"      Singh J, Khan M, Singh I. Silencing of Abcd1 and Abcd2 genes sensitizes astrocytes for inflammation: implication for X-adrenoleukodystrophy. J Lipid Res 2009; 50:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/27\">",
"      Powers JM, DeCiero DP, Ito M, et al. Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy. J Neuropathol Exp Neurol 2000; 59:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/28\">",
"      Powers JM, DeCiero DP, Cox C, et al. The dorsal root ganglia in adrenomyeloneuropathy: neuronal atrophy and abnormal mitochondria. J Neuropathol Exp Neurol 2001; 60:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/29\">",
"      Moser HW, Loes DJ, Melhem ER, et al. X-Linked adrenoleukodystrophy: overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients. Neuropediatrics 2000; 31:227.",
"     </a>",
"    </li>",
"    <li>",
"     Moser, HW, Moser, AB, Steinberg, SJ. X-linked adrenoleukodystrophy. GeneReviews. genetests.org.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/31\">",
"      Percy AK, Rutledge SL. Adrenoleukodystrophy and related disorders. Ment Retard Dev Disabil Res Rev 2001; 7:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/32\">",
"      Sakai S, Hirayama K, Ogura K, et al. Visual function of a patient with advanced adrenoleukodystrophy: comparison of luminance and color contrast sensitivities. Brain Dev 2008; 30:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/33\">",
"      Zackowski KM, Dubey P, Raymond GV, et al. Sensorimotor function and axonal integrity in adrenomyeloneuropathy. Arch Neurol 2006; 63:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/34\">",
"      Pillion JP, Moser HW, Raymond GV. Auditory function in adrenomyeloneuropathy. J Neurol Sci 2008; 269:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/35\">",
"      Pillion JP, Kharkar S, Mahmood A, et al. Auditory brainstem response findings and peripheral auditory sensitivity in adrenoleukodystrophy. J Neurol Sci 2006; 247:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/36\">",
"      Moser HW, Moser AB, Smith KD, et al. Adrenoleukodystrophy: phenotypic variability and implications for therapy. J Inherit Metab Dis 1992; 15:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/37\">",
"      Laureti S, Casucci G, Santeusanio F, et al. X-linked adrenoleukodystrophy is a frequent cause of idiopathic Addison's disease in young adult male patients. J Clin Endocrinol Metab 1996; 81:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/38\">",
"      Dubey P, Raymond GV, Moser AB, et al. Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening. J Pediatr 2005; 146:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/39\">",
"      Polgreen LE, Chahla S, Miller W, et al. Early diagnosis of cerebral X-linked adrenoleukodystrophy in boys with Addison's disease improves survival and neurological outcomes. Eur J Pediatr 2011; 170:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/40\">",
"      Maier EM, Kammerer S, Muntau AC, et al. Symptoms in carriers of adrenoleukodystrophy relate to skewed X inactivation. Ann Neurol 2002; 52:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/41\">",
"      Moser AB, Kreiter N, Bezman L, et al. Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol 1999; 45:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/42\">",
"      Unterberger U, Regelsberger G, Sundt R, et al. Diagnosis of X-linked adrenoleukodystrophy in blood leukocytes. Clin Biochem 2007; 40:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/43\">",
"      Boehm CD, Cutting GR, Lachtermacher MB, et al. Accurate DNA-based diagnostic and carrier testing for X-linked adrenoleukodystrophy. Mol Genet Metab 1999; 66:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/44\">",
"      Young RS, Ramer JC, Towfighi J, et al. Adrenoleukodystrophy: unusual computed tomographic appearance. Arch Neurol 1982; 39:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/45\">",
"      Esiri MM, Hyman NM, Horton WL, Lindenbaum RH. Adrenoleukodystrophy: clinical, pathological and biochemical findings in two brothers with the onset of cerebral disease in adult life. Neuropathol Appl Neurobiol 1984; 10:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/46\">",
"      MacDonald JT, Stauffer AE, Heitoff K. Adrenoleukodystrophy: early frontal lobe involvement on computed tomography. J Comput Assist Tomogr 1984; 8:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/47\">",
"      Melhem ER, Loes DJ, Georgiades CS, et al. X-linked adrenoleukodystrophy: the role of contrast-enhanced MR imaging in predicting disease progression. AJNR Am J Neuroradiol 2000; 21:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/48\">",
"      Eichler FS, Itoh R, Barker PB, et al. Proton MR spectroscopic and diffusion tensor brain MR imaging in X-linked adrenoleukodystrophy: initial experience. Radiology 2002; 225:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/49\">",
"      Eichler FS, Barker PB, Cox C, et al. Proton MR spectroscopic imaging predicts lesion progression on MRI in X-linked adrenoleukodystrophy. Neurology 2002; 58:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/50\">",
"      Dubey P, Fatemi A, Barker PB, et al. Spectroscopic evidence of cerebral axonopathy in patients with \"pure\" adrenomyeloneuropathy. Neurology 2005; 64:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/51\">",
"      Dubey P, Fatemi A, Huang H, et al. Diffusion tensor-based imaging reveals occult abnormalities in adrenomyeloneuropathy. Ann Neurol 2005; 58:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/52\">",
"      Fatemi A, Smith SA, Dubey P, et al. Magnetization transfer MRI demonstrates spinal cord abnormalities in adrenomyeloneuropathy. Neurology 2005; 64:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/53\">",
"      Marino S, De Luca M, Dotti MT, et al. Prominent brain axonal damage and functional reorganization in \"pure\" adrenomyeloneuropathy. Neurology 2007; 69:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/54\">",
"      Ratai E, Kok T, Wiggins C, et al. Seven-Tesla proton magnetic resonance spectroscopic imaging in adult X-linked adrenoleukodystrophy. Arch Neurol 2008; 65:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/55\">",
"      Furushima W, Inagaki M, Gunji A, et al. Early signs of visual perception and evoked potentials in radiologically asymptomatic boys with X-linked adrenoleukodystrophy. J Child Neurol 2009; 24:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/56\">",
"      Berger J, Pujol A, Aubourg P, Forss-Petter S. Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy. Brain Pathol 2010; 20:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/57\">",
"      Mahmood A, Dubey P, Moser HW, Moser A. X-linked adrenoleukodystrophy: therapeutic approaches to distinct phenotypes. Pediatr Transplant 2005; 9 Suppl 7:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/58\">",
"      Aubourg P, Blanche S, Jambaqu&eacute; I, et al. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med 1990; 322:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/59\">",
"      Cartier N, Aubourg P. Hematopoietic stem cell transplantation and hematopoietic stem cell gene therapy in X-linked adrenoleukodystrophy. Brain Pathol 2010; 20:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/60\">",
"      Petryk A, Polgreen LE, Chahla S, et al. No evidence for the reversal of adrenal failure after hematopoietic cell transplantation in X-linked adrenoleukodystrophy. Bone Marrow Transplant 2012; 47:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/61\">",
"      Shapiro E, Krivit W, Lockman L, et al. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet 2000; 356:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/62\">",
"      Peters C, Charnas LR, Tan Y, et al. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood 2004; 104:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/63\">",
"      Mahmood A, Raymond GV, Dubey P, et al. Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study. Lancet Neurol 2007; 6:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/64\">",
"      Miller WP, Rothman SM, Nascene D, et al. Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. Blood 2011; 118:1971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/65\">",
"      Moser HW, Moser AB, Hollandsworth K, et al. \"Lorenzo's oil\" therapy for X-linked adrenoleukodystrophy: rationale and current assessment of efficacy. J Mol Neurosci 2007; 33:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/66\">",
"      Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, et al. A two-year trial of oleic and erucic acids (\"Lorenzo's oil\") as treatment for adrenomyeloneuropathy. N Engl J Med 1993; 329:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/67\">",
"      van Geel BM, Assies J, Haverkort EB, et al. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with \"Lorenzo's oil\". J Neurol Neurosurg Psychiatry 1999; 67:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/68\">",
"      Moser HW, Raymond GV, Lu SE, et al. Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil. Arch Neurol 2005; 62:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/69\">",
"      Bezman L, Moser HW. Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes. Am J Med Genet 1998; 76:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/70\">",
"      Deon M, Wajner M, Sirtori LR, et al. The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy. J Neurol Sci 2006; 247:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/71\">",
"      Singh I, Pahan K, Khan M. Lovastatin and sodium phenylacetate normalize the levels of very long chain fatty acids in skin fibroblasts of X- adrenoleukodystrophy. FEBS Lett 1998; 426:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/72\">",
"      Pai GS, Khan M, Barbosa E, et al. Lovastatin therapy for X-linked adrenoleukodystrophy: clinical and biochemical observations on 12 patients. Mol Genet Metab 2000; 69:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/73\">",
"      Engelen M, Ofman R, Dijkgraaf MG, et al. Lovastatin in X-linked adrenoleukodystrophy. N Engl J Med 2010; 362:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/74\">",
"      Moser HW, Bezman L, Lu SE, Raymond GV. Therapy of X-linked adrenoleukodystrophy: prognosis based upon age and MRI abnormality and plans for placebo-controlled trials. J Inherit Metab Dis 2000; 23:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/75\">",
"      Gondcaille C, Depreter M, Fourcade S, et al. Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator. J Cell Biol 2005; 169:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/76\">",
"      Kemp S, Wanders RJ. X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism, ABC half-transporters and the complicated route to treatment. Mol Genet Metab 2007; 90:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/77\">",
"      Sanders RJ, Ofman R, Duran M, et al. Omega-oxidation of very long-chain fatty acids in human liver microsomes. Implications for X-linked adrenoleukodystrophy. J Biol Chem 2006; 281:13180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/78\">",
"      Morita M. [Adrenoleukodystrophy: molecular pathogenesis and development of therapeutic agents]. Yakugaku Zasshi 2007; 127:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/79\">",
"      Mastroeni R, Bensadoun JC, Charvin D, et al. Insulin-like growth factor-1 and neurotrophin-3 gene therapy prevents motor decline in an X-linked adrenoleukodystrophy mouse model. Ann Neurol 2009; 66:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/56/33673/abstract/80\">",
"      Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326:818.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6200 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-4C9EBFD82E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_56_33673=[""].join("\n");
var outline_f32_56_33673=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NEUROPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Childhood cerebral forms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Adrenomyeloneuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Addison disease only",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other presentations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Female carriers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Visual evoked responses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Dietary therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Gene therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6200\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6200|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/32/42498\" title=\"diagnostic image 1\">",
"      Brain MRI of a child with adrenoleukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6200|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/53/24413\" title=\"table 1A\">",
"      X-linked adrenoleukodystrophy A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/40/43660\" title=\"table 1B\">",
"      X-linked adrenoleukodystrophy B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/19/18748\" title=\"table 1C\">",
"      X-linked adrenoleukodystrophy C",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23369?source=related_link\">",
"      Causes and clinical manifestations of primary adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/46/44777?source=related_link\">",
"      Diagnosis of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17255?source=related_link\">",
"      Diagnosis of adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=related_link\">",
"      Diagnosis of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32426?source=related_link\">",
"      Disorders affecting the spinal cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/60/4038?source=related_link\">",
"      Krabbe disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/27/42421?source=related_link\">",
"      Metachromatic leukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/32/12809?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8570?source=related_link\">",
"      Peroxisomal disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32665?source=related_link\">",
"      Specific learning disabilities in children: Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31078?source=related_link\">",
"      Treatment of adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12408?source=related_link\">",
"      Unusual causes of adrenal insufficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_56_33674="Vascular structures 2";
var content_f32_56_33674=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=25\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=25\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 692px\">",
"   <div class=\"ttl\">",
"    Vascular structures most commonly seen in nonmelanocytic tumors",
"    <sup>",
"     [1-3]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 672px; height: 723px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The presence of a given vessel morphology is not exclusive to a particular diagnosis. For example, arborizing vessels are commonly seen in basal cell carcinoma but they can also be seen in melanoma and intradermal nevi. Another example would be that although hairpin vessels are commonly associated with seborrheic keratoses, they can also be seen in melanoma. With that said, this table highlights vessels that are most commonly associated with non-melanocytic tumors.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Zalaudek I, Kreusch J, Giacomel J, et al. How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part II. Nonmelanocytic skin tumors. J Am Acad Dermatol 2010; 63:377.",
"       </li>",
"       <li>",
"        Zalaudek I, Kreusch J, Giacomel J, et al. How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part I. Melanocytic skin tumors. J Am Acad Dermatol 2010; 63:361.",
"       </li>",
"       <li>",
"        Argenziano G, Zalaudek I, Corona R, et al. Vascular structures in skin tumors: a dermoscopy study. Arch Dermatol 2004; 140:1485.",
"       </li>",
"       <li>",
"        Pan Y, Chamberlain AJ, Bailey M, et al. Dermatoscopy aids in the diagnosis of the solitary red scaly patch or plaque-features distinguishing superficial basal cell carcinoma, intraepidermal carcinoma, and psoriasis. J Am Acad Dermatol 2008; 59:268.",
"       </li>",
"       <li>",
"        Braun RP, Rabinovitz HS, Krischer J, et al. Dermoscopy of pigmented seborrheic keratosis: a morphological study. Arch Dermatol 2002; 138:1556.",
"       </li>",
"       <li>",
"        Ka VS, Clark-Loeser L, Marghoob AA. Vascular pattern in seborrheic keratoses and melanoma. Dermatol Surg 2004; 30:75.",
"       </li>",
"       <li>",
"        Altamura D, Menzies SW, Argenziano G, et al. Dermatoscopy of basal cell carcinoma: morphologic variability of global and local features and accuracy of diagnosis. J Am Acad Dermatol 2010; 62:67.",
"       </li>",
"       <li>",
"        Zalaudek I, Giacomel J, Argenziano G, et al. Dermoscopy of facial nonpigmented actinic keratosis. Br J Dermatol 2006; 155:951.",
"       </li>",
"      </ol>",
"      <br>",
"       Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_56_33674=[""].join("\n");
var outline_f32_56_33674=null;
var title_f32_56_33675="Metabisulfite challenge";
var content_f32_56_33675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F83722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F83722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Liquid and capsule challenge procedures for potassium metabisulfite (sulfites)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Food additive",
"       </td>",
"       <td class=\"subtitle1\">",
"        Route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Interval time",
"       </td>",
"       <td class=\"subtitle1\">",
"        Monitoring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Potassium metabisulfite",
"       </td>",
"       <td>",
"        Skin prick testing",
"       </td>",
"       <td>",
"        <p>",
"         0.001 mg/mL",
"        </p>",
"        <p>",
"         0.01 mg/mL",
"        </p>",
"        <p>",
"         0.1 mg/mL",
"        </p>",
"        <p>",
"         1 mg/mL",
"        </p>",
"       </td>",
"       <td>",
"        15 minutes",
"       </td>",
"       <td>",
"        Wheal/erythema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intradermal",
"       </td>",
"       <td>",
"        0.02 mL of 0.001 mg/mL solution",
"       </td>",
"       <td>",
"        15 minutes",
"       </td>",
"       <td>",
"        Wheal/erythema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral (solution)",
"       </td>",
"       <td>",
"        1 mg, 10 mg, 25 mg, 50 mg, 100 mg",
"       </td>",
"       <td>",
"        20 minutes in between doses",
"       </td>",
"       <td>",
"        Spirometry prior to each dose and following each dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral (capsule)",
"       </td>",
"       <td>",
"        1 mg, 10 mg, 25 mg, 50 mg, 100 mg",
"       </td>",
"       <td>",
"        30 minutes in between doses",
"       </td>",
"       <td>",
"        Spirometry prior to each dose and following each dose",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bush RK, Zoratti E, Taylor SL. Diagnosis of sulfite and aspirin sensitivity. Clin Rev Allergy 1990; 8:159-78.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_56_33675=[""].join("\n");
var outline_f32_56_33675=null;
var title_f32_56_33676="Side effects of quinidine";
var content_f32_56_33676=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Side effects induced by quinidine",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Side effect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Relative frequency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Cardiovascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Proarrhythmia",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Torsades de pointes",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prolonged QT interval",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypotension",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sinus arrest",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Heart failure",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        AV block",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Gastrointestinal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diarrhea",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nausea, abdominal pain",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatotoxicity",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Central nervous system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cinchonism",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Psychosis",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Depression",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Blurred vision",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Hematologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thrombocytopenia",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Agranulocytosis",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemolytic anemia",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypoprothrombinemia",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fever",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lupus-like syndrome",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Major side effects induced by quinidine and their relative frequency.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_56_33676=[""].join("\n");
var outline_f32_56_33676=null;
var title_f32_56_33677="Frank Starling curves in HF";
var content_f32_56_33677=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Frank-Starling curves in HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 330px; height: 236px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Idealized family of Frank-Starling curves produced by worsening ventricular function in heart failure. In ventricles with normal cardiac performance, there is a steep and positive relationship between increased cardiac filling pressures (as estimated from the left ventricular end-diastolic or pulmonary capillary wedge pressure) and increased stroke volume or cardiac output (top curve). In comparison, during progression from mild to severe myocardial dysfunction, this relationship is right-shifted (ie, a higher filling pressure is required to achieve the same cardiac output) and flattened so that continued increases in left heart filling pressures lead to minimal increases in cardiac output at the possible expense of pulmonary edema. The onset of mild heart failure results in an initial reduction in cardiac function (point B), a change that can be normalized, at least at rest, by raising the LVEDP via fluid retention (point C). Diuretic therapy reduces left ventricular filling pressure at the expense of mildly decreased cardiac output (moving from point C to point B). In comparison, normalization of stroke volume is not attainable in severe heart failure (bottom curve).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_56_33677=[""].join("\n");
var outline_f32_56_33677=null;
var title_f32_56_33678="Diagram of a water treatment system for HD";
var content_f32_56_33678=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F81113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F81113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Schematic diagram of a water treatment system for hemodialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 336px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic diagram of one possible water treatment system that begins with feed water entering the system at the left side. In our example (see text and tables), deionization (DI) has been included in addition to reverse osmosis because the required reduction in fluoride was close to the limit that can be achieved by reverse osmosis alone. Because a deionizer was included after the reverse osmosis unit, a bacteria- and endotoxin-retentive filter was added to protect the water storage and distribution system from bacterial contamination.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_56_33678=[""].join("\n");
var outline_f32_56_33678=null;
var title_f32_56_33679="Standard cricothyrotomy step four";
var content_f32_56_33679=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Standard cricothyrotomy step four",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <font class=\"red\">",
"     <font color=\"black\">",
"      Insert the tracheal hook and ask an assistant to provide upward traction.",
"     </font>",
"    </font>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Custalow CB. Color Atlas of Emergency Department Procedures, Elsevier Saunders, Philadelphia 2005. Copyright &copy;2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_56_33679=[""].join("\n");
var outline_f32_56_33679=null;
